<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_5</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Atrophy</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Myostatin</author-keyword>
<author-keyword>Insulin signalling</author-keyword>
<author-keyword>Ubiquitin-proteasome system</author-keyword>
<author-keyword>Autophagy</author-keyword>
<author-keyword>Inflammation</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Signaling Pathways That Promote Muscle Catabolism in Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.E.</ce:initials> 
<ce:surname>Gilda</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials> 
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<affiliation>
<organization>Technion-Israel Institute of Technology</organization>
<state>Haifa</state>
<country iso-code="ISR"/>
<ce:source-text>Technion-Israel Institute of Technology, Haifa, Israel.</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>S.</ce:initials> 
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
<ce:e-address>shenhavc@technion.ac.il</ce:e-address>
</person>
<affiliation>
<organization>Technion-Israel Institute of Technology</organization>
<state>Haifa</state>
<country iso-code="ISR"/>
<ce:source-text>Technion-Israel Institute of Technology, Haifa, Israel.</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cachexia is a severe loss of muscle mass in chronic disease, often accompanied by meta- bolic dysfunction, fatigue, loss of appetite, general weight loss, and poor patient outcomes. This debilitating condition is highly prevalent in cancer patients, lowering their quality of life and likelihood of survival. Pre- vention of muscle loss is expected to prolong survival, however, currently there are no accepted effective treatments, and cachexia is usually only diagnosed in advanced stages when therapeutic intervention is particularly challenging. Development and administration of effective therapies require foundational understanding of the underlying mechanisms that promote protein breakdown and cause wasting. Recently, the sequence of key molec- ular and cellular events driving catabolism, and the regulatory signals stimulating overall proteolysis, have become clearer from studies on animal models for muscle atrophy. Differ- ent types of atrophy share common transcrip- tional changes and proteolytic pathways that activate degradation of soluble and contractile myofibrillar proteins; consequently, identified key regulators of these common mechanisms should be attractive drug targets for treatment of numerous wasting conditions. In this chapter, we discuss our current knowledge on these catabolic events and key regulators, which orchestrate the continuous progression of the atrophy process from its initial cues. We also highlight promising avenues of research for better understanding and treating cancer cachexia.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">978-3-031-07272-7</isbn>
<isbn type="electronic" length="13">978-3-031-09518-4</isbn>
<volisspag>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="261">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle regulates metabolism viainter-organ cross talk:roles inheal thand disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Campos</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Lopez-Pedrosa</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>796</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés,J.M.,Campos,N.,Lopez-Pedrosa,J.M.,etal.:Skeletal muscle regulates metabolism viainter-organ cross talk:roles inheal than ddisease.J.Am.Med.Dir.Assoc.17(9),789–796(2016)</ref-fulltext>
<ce:source-text>Argilés,J.M.,Campos,N.,Lopez-Pedrosa,J.M.,etal.:Skeletal muscle regulates metabolism viainter-organ cross talk:roles inheal than ddisease.J.Am.Med.Dir.Assoc.17(9),789–796(2016)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of muscle a trophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bonaldo</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>DMM Disease Models and Mechanisms</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Bonaldo,P.,Sandri,M.:Cellular and molecular mechanisms of muscle a trophy.DMM Disease Models and Mechanisms.(2013)</ref-fulltext>
<ce:source-text>Bonaldo,P.,Sandri,M.:Cellular and molecular mechanisms of muscle a trophy.DMM Disease Models and Mechanisms.(2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>The Lethal Pheno type  of Cancer: The Molecular Basis of Death Due to Malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.D.</ce:initials>
<ce:surname>Loberg</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Bradley</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Tomlins</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J.Clin</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3322/canjclin.57.4.225</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loberg,R.D.,Bradley,D.A.,Tomlins,S.A.,etal.:TheLethal Pheno type of Cancer: The Molecular Basis of Death Due to Malignancy.CA Cancer J.Clin.(2007).https://doi.org/10.3322/canjclin.57.4.225</ref-fulltext>
<ce:source-text>Loberg,R.D.,Bradley,D.A.,Tomlins,S.A.,etal.:TheLethal Pheno type of Cancer: The Molecular Basis of Death Due to Malignancy.CA Cancer J.Clin.(2007).https://doi.org/10.3322/canjclin.57.4.225</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis and cachexia: alongside in clinics,but not so in animal models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tomasin</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.B.M.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>A.C.B.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Cominetti</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Tomasin,R.,Martin,A.C.B.M.,Cominetti,M.R.:Metastasis and cachexia: alongside inclinics,but not so in animal models.J.Cachexia Sarcopenia Muscle(2019)</ref-fulltext>
<ce:source-text>Tomasin,R.,Martin,A.C.B.M.,Cominetti,M.R.:Metastasis and cachexia: alongside inclinics,but not so in animal models.J.Cachexia Sarcopenia Muscle(2019)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Body composition,symptoms,and survival in advanced cancer patients referred to a phase I service</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.A.</ce:initials>
<ce:surname>Parsons</ce:surname>
<ce:given-name>H.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Dhillon</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ref-fulltext>
<ce:source-text>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol.Rev</ref-sourcetitle>
<ref-publicationyear first="2009"/>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by Act RIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2010.07.011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ref-fulltext>
<ce:source-text>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Orpí</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s13539-011-0049-z</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ref-fulltext>
<ce:source-text>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and β-2 agonist</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.29930</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ref-fulltext>
<ce:source-text>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The metabolic basis of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Alvarez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.J.</ce:initials>
<ce:surname>López-Soriano</ce:surname>
<ce:given-name>F.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med.Res.Rev</ref-sourcetitle>
<ref-publicationyear first="1997"/>
</ref-info>
<ref-fulltext>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ref-fulltext>
<ce:source-text>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Stadler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur.J.Transl.Myol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4081/ejtm.2018.7590</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018. 7590</ref-fulltext>
<ce:source-text>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018. 7590</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english> Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Cachexia.Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12360</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/ jcsm.12360</ref-fulltext>
<ce:source-text>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/ jcsm.12360</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Colotta</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Allavena</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sica</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2009"/>
</ref-info>
<ref-fulltext>Colotta, F., Allavena, P., Sica, A., et al.: Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ref-fulltext>
<ce:source-text>Colotta, F., Allavena, P., Sica, A., et al.: Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: the next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell. (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell. (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-related inflammation and treatment effectiveness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.I.</ce:initials>
<ce:surname>Diakos</ce:surname>
<ce:given-name>C.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Charles</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.J.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
</ref-info>
<ref-fulltext>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ref-fulltext>
<ce:source-text>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and systemic inflammation: treat the tumour and treat the host</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.D.</ce:initials>
<ce:surname>Roxburgh</ce:surname>
<ce:given-name>C.S.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.2014.90</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/ bjc.2014.90</ref-fulltext>
<ce:source-text>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/ bjc.2014.90</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.C.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>D.A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Wigmore</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.bjc.6604828</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ref-fulltext>
<ce:source-text>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Dülger</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Alici</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Şekeroǧlu</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Clin.Pract</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1368-5031.2004.00149.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031. 2004.00149.x</ref-fulltext>
<ce:source-text>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031. 2004.00149.x</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Macciò</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Madeddu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Mol.Med</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s001090100234</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/ s001090100234</ref-fulltext>
<ce:source-text>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/ s001090100234</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.S.</ce:initials>
<ce:surname>DenBrekel</ce:surname>
<ce:given-name>Staal-van</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Dentener</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.M.W.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Oncol</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.1995.13.10.2600</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Staal-van Den Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13. 10.2600</ref-fulltext>
<ce:source-text>Staal-van Den Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13. 10.2600</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Tas</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Duranyildiz</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Argon</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med.Oncol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1385/MO:22:4:353</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ref-fulltext>
<ce:source-text>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: From tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>GenesDev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Gonzalez,H.,Hagerling,C.,Werb,Z.:Roles of the immune system in cancer: From tumorinitiation to metastatic progression.GenesDev.(2018)</ref-fulltext>
<ce:source-text>Gonzalez,H.,Hagerling,C.,Werb,Z.:Roles of the immune system in cancer: From tumorinitiation to metastatic progression.GenesDev.(2018)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>The immune contexture in human tumours: impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.H.</ce:initials>
<ce:surname>Fridman</ce:surname>
<ce:given-name>W.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pagès</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Saut s-Fridman</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Galon</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Fridman, W.H., Pagès, F., Saut s-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ref-fulltext>
<ce:source-text>Fridman, W.H., Pagès, F., Saut s-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Casneuf</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.E.</ce:initials>
<ce:surname>Axel</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Targets Therapy</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.2147/BCTT.S92414</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https:// doi.org/10.2147/BCTT.S92414</ref-fulltext>
<ce:source-text>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https:// doi.org/10.2147/BCTT.S92414</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Edwardson</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Boudreau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Mapletoft</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0183662</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi. org/10.1371/journal.pone.0183662</ref-fulltext>
<ce:source-text>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi. org/10.1371/journal.pone.0183662</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sprowl</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Reed</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Armstrong</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/bcr3083</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10. 1186/bcr3083</ref-fulltext>
<ce:source-text>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10. 1186/bcr3083</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english> Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Frost</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.J.</ce:initials>
<ce:surname>Nystrom</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.S.</ce:initials>
<ce:surname>Jefferson</ce:surname>
<ce:given-name>L.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Lang</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Physiol</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am.J.Physiol.Endocrinol.Metab</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00359.2006</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C. H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ref-fulltext>
<ce:source-text>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C. H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.P.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>John</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.04-2364com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ref-fulltext>
<ce:source-text>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Edwardson</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.D.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.A.</ce:initials>
<ce:surname>Chambers</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Physiol</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am.J.Physiol.Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00041.2008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi. org/10.1152/ajpcell.00041.2008</ref-fulltext>
<ce:source-text>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi. org/10.1152/ajpcell.00041.2008</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/ PKB pathway and induces atrophy and apoptosis in L6 myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.J.N.</ce:initials>
<ce:surname>Sishi</ce:surname>
<ce:given-name>B.J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Engelbrecht</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cyto.2011.01.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/ PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10. 1016/j.cyto.2011.01.009</ref-fulltext>
<ce:source-text>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/ PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10. 1016/j.cyto.2011.01.009</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Tumors secreting human TNF/cachectin induce cachexia in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Oliff</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Defeo-Jones</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Boyer</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(87)90028-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092- 8674(87)90028-6</ref-fulltext>
<ce:source-text>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092- 8674(87)90028-6</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>A placebocontrolled, double-blind trial of infliximab for cancerassociated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.L.</ce:initials>
<ce:surname>Ritter</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Dueck</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2009.06.020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>. Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebocontrolled, double-blind trial of infliximab for cancerassociated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j. lungcan.2009.06.020</ref-fulltext>
<ce:source-text>. Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebocontrolled, double-blind trial of infliximab for cancerassociated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j. lungcan.2009.06.020</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and cachexia in ApcMin/+ mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.G.</ce:initials>
<ce:surname>Berger</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.M.O.</ce:initials>
<ce:surname>Pena</ce:surname>
<ce:given-name>M.M.O.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Physiol</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am.J.Physiol.Regul.Integr.Comp.Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00716.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ref-fulltext>
<ce:source-text>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 as a key regulator of muscle mass during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exerc.Sport Sci.Rev</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/JES.0b013e3181f44f11</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES. 0b013e3181f44f11</ref-fulltext>
<ce:source-text>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES. 0b013e3181f44f11</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Maingay</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol.Rep</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or_00000328</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https:// doi.org/10.3892/or_00000328</ref-fulltext>
<ce:source-text>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https:// doi.org/10.3892/or_00000328</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between weight loss and interleukin 6 in non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.R.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>H.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Crilly</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.1996.294</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ref-fulltext>
<ce:source-text>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fujlta</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Tsujinaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Yano</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="1996"/>
</ref-info>
<ref-fulltext>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:53.0.CO;2-Z</ref-fulltext>
<ce:source-text>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:53.0.CO;2-Z</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Baynes</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.W.</ce:initials>
<ce:surname>Welle</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0024650</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/ journal.pone.0024650</ref-fulltext>
<ce:source-text>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/ journal.pone.0024650</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Bayliss</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Schuster</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert.Opin.Biol.Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1517/14712598.2011.627850</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598. 2011.627850</ref-fulltext>
<ce:source-text>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598. 2011.627850</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J.</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-7537com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06- 7537com</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06- 7537com</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.C.</ce:initials>
<ce:surname>Biol</ce:surname>
<ce:given-name>Cell</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200909117</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/ jcb.200909117</ref-fulltext>
<ce:source-text>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/ jcb.200909117</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 in skeletal muscle function and disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Guadagnin</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Mázala</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Mol.Sci</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ref-fulltext>
<ce:source-text>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Sala</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Sacco</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr.Opin.Clin.Nutr.Metab.Care</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ref-fulltext>
<ce:source-text>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kunzevitzky</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0022538</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10. 1371/journal.pone.0022538</ref-fulltext>
<ce:source-text>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10. 1371/journal.pone.0022538</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2013.07.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https:// doi.org/10.1016/j.cmet.2013.07.012</ref-fulltext>
<ce:source-text>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https:// doi.org/10.1016/j.cmet.2013.07.012</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Cleary</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Hanson</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am.J.Physiol.Regul.Integr.Comp.Physiol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00247.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ref-fulltext>
<ce:source-text>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreaticcancer-inducedcachexiaisJak2-dependentinmice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gilaber</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Calvo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Airoldi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Cell.Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.24580</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gilabert,M.,Calvo,E.,Airoldi,A.,etal.:Pancreaticcancer-inducedcachexiaisJak2-dependentinmice.J.Cell.Physiol.(2014).https://doi.org/10.1002/jcp.24580</ref-fulltext>
<ce:source-text>Gilabert,M.,Calvo,E.,Airoldi,A.,etal.:Pancreaticcancer-inducedcachexiaisJak2-dependentinmice.J.Cell.Physiol.(2014).https://doi.org/10.1002/jcp.24580</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.S.</ce:initials>
<ce:surname>Silva</ce:surname>
<ce:given-name>K.A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Biol</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Biol.Chem</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M115.641514</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ref-fulltext> 
<ce:source-text>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol.Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.phrs.2020.104871</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020. 104871</ref-fulltext>
<ce:source-text>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020. 104871</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cai</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Frantz</ce:surname>
<ce:given-name>J.</ce:given-name>
<ce:degree>Jr.</ce:degree>
</author>
<author seq="3">
<ce:initials>E.T.</ce:initials>
<ce:surname>Nicholas</ce:surname>
<ce:given-name>E.T.</ce:given-name>
<ce:degree>Jr.</ce:degree>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
</ref-info>
<ref-fulltext>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ref-fulltext>
<ce:source-text>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Thoma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lightfoot</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> In: Advances in experimental medicine and biology</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ref-fulltext>
<ce:source-text>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ashall</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Horton</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.E.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1164860</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ref-fulltext>
<ce:source-text>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.R.</ce:initials>
<ce:surname>Butchbach</ce:surname>
<ce:given-name>M.E.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Sahenk</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoSOne</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2005.10.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10. 1016/j.ccr.2005.10.004</ref-fulltext>
<ce:source-text>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10. 1016/j.ccr.2005.10.004</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Rhoads</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pacelli</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ejca.2009.10.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ref-fulltext>
<ce:source-text>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Kawamura</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Morishita</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Tomita</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>GeneTher</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.gt.3300819</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10. 1038/sj.gt.3300819</ref-fulltext>
<ce:source-text>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10. 1038/sj.gt.3300819</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>Grossberg</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Krasnow</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEBJ</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.13-230375</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj. 13-230375</ref-fulltext>
<ce:source-text>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj. 13-230375</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Neurobiology of inflammationassociated anorexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Gautron</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front.Neurosci</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/neuro.23.003.2009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gautron, L.: Neurobiology of inflammationassociated anorexia. Front. Neurosci. (2009). https:// doi.org/10.3389/neuro.23.003.2009</ref-fulltext>
<ce:source-text>Gautron, L.: Neurobiology of inflammationassociated anorexia. Front. Neurosci. (2009). https:// doi.org/10.3389/neuro.23.003.2009</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cole</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.R.</ce:initials>
<ce:surname>Kleckner</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSMClin.Reports</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.17987/jcsm-cr.v3i2.65</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https:// doi.org/10.17987/jcsm-cr.v3i2.65</ref-fulltext>
<ce:source-text>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https:// doi.org/10.17987/jcsm-cr.v3i2.65</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Fuller</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Hartland</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.T.</ce:initials>
<ce:surname>Maloney</ce:surname>
<ce:given-name>L.T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Davison</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br.J.SportsMed</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ref-fulltext>
<ce:source-text>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lønbro</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Dalgas</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Primdahl</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Radiother.Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.radonc.2013.07.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial..Radiother.Oncol.(2013).https://doi.org/10.1016/j.radonc.2013.07.002</ref-fulltext>
<ce:source-text>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial..Radiother.Oncol.(2013).https://doi.org/10.1016/j.radonc.2013.07.002</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise interventions on health-related quality of life for cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.I.</ce:initials>
<ce:surname>Mishra</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Scherer</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.M.</ce:initials>
<ce:surname>Geigle</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cochrane Database Syst. Rev</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ref-fulltext>
<ce:source-text>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: a meta-analysis of randomized control trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.B.</ce:initials>
<ce:surname>Nadler</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Desnoyers</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.M.</ce:initials>
<ce:surname>Langelier</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Amir</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.PainSympt.Manag</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: a meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ref-fulltext>
<ce:source-text>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: a meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Physical exercise for cancer patients with advanced disease: a randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:surname>Oldervoll</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.H.</ce:initials>
<ce:surname>Loge</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lydersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1634/theoncologist.2011-0133</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist. 2011-0133</ref-fulltext>
<ce:source-text>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist. 2011-0133</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise training as therapy for cardiac and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.R.R.</ce:initials>
<ce:surname>Alves</ce:surname>
<ce:given-name>C.R.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.F.</ce:initials>
<ce:surname>DaCunha</ce:surname>
<ce:given-name>T.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>Paixão</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.C.</ce:initials>
<ce:surname>Brum</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>LifeSci</ref-sourcetitle>
<ref-publicationyear first="2015"/>
</ref-info>
<ref-fulltext>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ref-fulltext>
<ce:source-text>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english> Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Sugimoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Fujimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.201802430R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ref-fulltext>
<ce:source-text>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gleeson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Bishop</ce:surname>
<ce:given-name>N.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.J.</ce:initials>
<ce:surname>Stensel</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Immunol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ref-fulltext>
<ce:source-text>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Kasapis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Coll. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
</ref-info>
<ref-fulltext>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J. Am. Coll. Cardiol. (2005)</ref-fulltext>
<ce:source-text>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J. Am. Coll. Cardiol. (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>The anti- inflammatory effect of exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.W.</ce:initials>
<ce:surname>Petersen</ce:surname>
<ce:given-name>A.M.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Pedersen</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
</ref-info>
<ref-fulltext>Petersen, A.M.W., Pedersen, B.K.: The anti- inflammatory effect of exercise. J. Appl. Physiol. (2005)</ref-fulltext>
<ce:source-text>Petersen, A.M.W., Pedersen, B.K.: The anti- inflammatory effect of exercise. J. Appl. Physiol. (2005)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english> The discovery of TGF-β: a historical perspective</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> In: The TGF-β Family</ref-sourcetitle>
<ref-publicationyear first="2008"/>
</ref-info>
<ref-fulltext>Moses, H.L.: The discovery of TGF-β: a historical perspective. In: The TGF-β Family (2008)</ref-fulltext>
<ce:source-text>Moses, H.L.: The discovery of TGF-β: a historical perspective. In: The TGF-β Family (2008)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β signaling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Syed</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcb.25496</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ref-fulltext>
<ce:source-text>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the myostatin signaling pathway to treat muscle wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>H.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ref-fulltext>
<ce:source-text>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin/activin pathway antagonism: molecular basis and therapeutic potentia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>H.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Cassar-Malek</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Passelaigue</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Bernard</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Genomics</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2164-8-63</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ref-fulltext>
<ce:source-text>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1038/387083a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regula- tion of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/ 10.1038/387083a0</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regula- tion of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/ 10.1038/387083a0</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Regula- tion of skeletal muscle mass in mice by a new TGF-β superfamily member</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1038/387083a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regula- tion of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/ 10.1038/387083a0</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regula- tion of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/ 10.1038/387083a0</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozy- gote dogs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Mosher</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Quignon</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.D.</ce:initials>
<ce:surname>Bustamante</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS Genet</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10. 1371/journal.pgen.0030079</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozy- gote dogs. PLoS Genet. (2007). https://doi.org/10. 1371/journal.pgen.0030079</ref-fulltext>
<ce:source-text>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozy- gote dogs. PLoS Genet. (2007). https://doi.org/10. 1371/journal.pgen.0030079</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin mutation associated with gross muscle hypertrophy in a child</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Schuelk</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.R.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>K.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.E.</ce:initials>
<ce:surname> Stolz</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1056/NEJMoa040933</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ref-fulltext>
<ce:source-text>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Durieux</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Amirouch</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Banze</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1210/en.2006-1500</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/ 10.1210/en.2006-1500</ref-fulltext>
<ce:source-text>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/ 10.1210/en.2006-1500</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of cachexia in mice by systemically administered myostatin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.V.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.G.</ce:initials>
<ce:surname>Koniaris</ce:surname>
<ce:given-name>L.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>296</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1486</first-page>
<last-page>1488</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1069525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ref-fulltext>
<ce:source-text>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english> Myostatin from the heart: local and sys- temic actions in cardiac failure and muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Auger-Messier</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Molkentin</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Heineke</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https:// doi.org/10.1152/ajpheart.00200.2011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and sys- temic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https:// doi.org/10.1152/ajpheart.00200.2011</ref-fulltext>
<ce:source-text>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and sys- temic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https:// doi.org/10.1152/ajpheart.00200.2011</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbart</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.M.</ce:initials>
<ce:surname>Scharf</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Duncker</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoSOne</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone. 0080454</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone. 0080454</ref-fulltext>
<ce:source-text>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone. 0080454</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.F.</ce:initials>
<ce:surname>Gonzalez-Cadavi</ce:surname>
<ce:given-name>N.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci</ref-sourcetitle>
<ref-text>USA</ref-text>
<ref-publicationyear first="1998"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.95.25.14938</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ref-fulltext>
<ce:source-text>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Role of activin A and myostatin in human cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Loumaye</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>De Barsy</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Nachit</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url"> https:// doi.org/10.1210/jc.2014-4318</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https:// doi.org/10.1210/jc.2014-4318</ref-fulltext>
<ce:source-text>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https:// doi.org/10.1210/jc.2014-4318</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Sinha-Hikim</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Nutr. Health Aging</ref-sourcetitle>
<ref-publicationyear first="2002"/>
</ref-info>
<ref-fulltext>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ref-fulltext>
<ce:source-text>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>de Kretser</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.P.</ce:initials>
<ce:surname>Hedger</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>The immunoregulatory and fibrotic roles of activin A in allergic asthma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rolland</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Clin. Exp. Allergy</ref-sourcetitle>
<ref-publicationyear first="2017"/>
</ref-info>
<ref-fulltext>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ref-fulltext>
<ce:source-text>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english> Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mansell</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Patella</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci</ref-sourcetitle>
<ref-text> USA</ref-text>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0705971104</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext> Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ref-fulltext>
<ce:source-text> Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin is a direct regulator of osteoclast differen- tiation and its inhibition reduces inflammatory joint destruction in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Dankbar</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Fennen</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Brunert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1038/nm.3917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differen- tiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/ 10.1038/nm.3917</ref-fulltext>
<ce:source-text>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differen- tiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/ 10.1038/nm.3917</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney diseas</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Rajan</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https:// doi.org/10.1096/fj.10-176917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemicinflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https:// doi.org/10.1096/fj.10-176917</ref-fulltext>
<ce:source-text>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemicinflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https:// doi.org/10.1096/fj.10-176917</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english> Changes in myostatin signaling in non-weight-losing cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1245/s10434-011-1720-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext> Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/ 10.1245/s10434-011-1720-5</ref-fulltext>
<ce:source-text> Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/ 10.1245/s10434-011-1720-5</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Serum immunoreactive activin A levels in normal subjects and patients with various diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Harada</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shintani</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Sakamoto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/ jc.81.6.2125</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/ jc.81.6.2125</ref-fulltext>
<ce:source-text>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/ jc.81.6.2125</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer meta- static to the bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Rini</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2007"/>
</ref-info>
<ref-fulltext>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer meta- static to the bone. Anticancer Res. (2007)</ref-fulltext>
<ce:source-text>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer meta- static to the bone. Anticancer Res. (2007)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A circulating levels in patients with bone metastasis from breast or prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Leto</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s10585- 006-9010-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext> Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585- 006-9010-5</ref-fulltext>
<ce:source-text> Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585- 006-9010-5</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Mus- cle myostatin signalling is enhanced in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https:// doi.org/10.1111/j.1365-2362.2008.01970.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Mus- cle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https:// doi.org/10.1111/j.1365-2362.2008.01970.x</ref-fulltext>
<ce:source-text>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Mus- cle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https:// doi.org/10.1111/j.1365-2362.2008.01970.x</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.B.</ce:initials>
<ce:surname>Klimek</ce:surname>
<ce:given-name>Benny</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Link</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbrc.2009.12.123</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Matsumoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-15040-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ref-fulltext>
<ce:source-text>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexi</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.M.</ce:initials>
<ce:surname>O’Connell</ce:surname>
<ce:given-name>T.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/ cancers11091222</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/ cancers11091222</ref-fulltext>
<ce:source-text>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/ cancers11091222</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Greco</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tomkötter</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.K.</ce:initials>
<ce:surname>Vahle</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoSOne</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/ 10.1371/journal.pone.0132786</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/ 10.1371/journal.pone.0132786</ref-fulltext>
<ce:source-text>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/ 10.1371/journal.pone.0132786</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ref-fulltext>
<ce:source-text>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.S.</ce:initials>
<ce:surname>Jameson</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.D.</ce:initials>
<ce:surname>Von Hoff</ce:surname>
<ce:given-name>D.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Weiss</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.
org/10.1200/jco.2012.30.15_suppl.2516</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi. org/10.1200/jco.2012.30.15_suppl.2516</ref-fulltext>
<ce:source-text>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi. org/10.1200/jco.2012.30.15_suppl.2516</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Molec- ular therapeutic strategies targeting pancreatic cancer induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Yakovenko</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cameron</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.G.</ce:initials>
<ce:surname>Trevino</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Gastroint</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J. Gastroint. Surg</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4240/wjgs.v10.i9.95</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95 </ref-fulltext>
<ce:source-text>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95 </ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Dieli-Conwright</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.M.</ce:initials>
<ce:surname>Spektor</ce:surname>
<ce:given-name>T.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Rice</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Strength Cond. Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1519/JSC. 0b013e318251083f</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentricexercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC. 0b013e318251083f</ref-fulltext>
<ce:source-text>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentricexercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC. 0b013e318251083f</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Matsakas</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Friedel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Hertrampf</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Diel</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Physiol. Scand</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ref-fulltext>
<ce:source-text>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Bassi</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials> P.D.G.</ce:initials>
<ce:surname>Bueno</ce:surname>
<ce:given-name>P.D.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.O.</ce:initials>
<ce:surname>Nonaka</ce:surname>
<ce:given-name>K.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Arch. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1590/2359-3997000000028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ref-fulltext>
<ce:source-text>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin decreases with aerobic exercise and associates with insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Hittel</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Axelson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sarna</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ref-fulltext>
<ce:source-text>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Kopple</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.H.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>A.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Ren. Nutr</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1053/j.jrn.2006.04.028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ref-fulltext>
<ce:source-text>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Lenk</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Schur</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Linke</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hfp020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ref-fulltext>
<ce:source-text>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular adaptations to aerobic exercise training in skeletal muscle of older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Konopka</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Douglass</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.A.</ce:initials>
<ce:surname>Kaminsky</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Gerontol. Ser a Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/gerona/glq109</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ref-fulltext>
<ce:source-text>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Ryan</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Blumenthal</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.K.</ce:initials>
<ce:surname>Ortmeyer</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Obesity</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20216</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ref-fulltext>
<ce:source-text>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Coutinho</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>Chapman</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>13</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.mce.2010.04.005</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ref-fulltext>
<ce:source-text>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Eda</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1990"/>
</ref-info>
<ref-fulltext>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ref-fulltext>
<ce:source-text>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Fagan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Roegner</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI118421</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ref-fulltext>
<ce:source-text>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Szumowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.R.</ce:initials>
<ce:surname>Levasseur</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0106489</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ref-fulltext>
<ce:source-text>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Schakman</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Kalista</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Barbé</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of gluconeogenesis by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Exton</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Monogr. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="1979"/>
</ref-info>
<ref-fulltext>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ref-fulltext>
<ce:source-text>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Morgan</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sherlock</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.L.</ce:initials>
<ce:surname>Gathercole</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Diabetes</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.2337/db09-0525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ref-fulltext>
<ce:source-text>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Nakao</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Hirasaka</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Goto</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1128/mcb.01347-08</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ref-fulltext>
<ce:source-text>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ohkawa</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.09-151480</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ref-fulltext>
<ce:source-text>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Giorgino</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Pedrini</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Matera</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.J.</ce:initials>
<ce:surname>Smithi</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.272.11.7455</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ref-fulltext>
<ce:source-text>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.L.</ce:initials>
<ce:surname>In</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">. https://doi.org/10.1172/JCI38770</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>. Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ref-fulltext>
<ce:source-text>. Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Kuo</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Lew</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Mayba</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Proc. Natl. Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1111334109 </ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ref-fulltext>
<ce:source-text>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english> Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Artaza</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https:// doi.org/10.1002/jcp.10044</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https:// doi.org/10.1002/jcp.10044</ref-fulltext>
<ce:source-text>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https:// doi.org/10.1002/jcp.10044</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00487.2002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ref-fulltext>
<ce:source-text>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McFarlane</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Plummer</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">. https://doi.org/10.1002/jcp.20757</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ref-fulltext>
<ce:source-text>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cersosimo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.W.T.</ce:initials>
<ce:surname>Pisters</ce:surname>
<ce:given-name>P.W.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pesola</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1991"/>
</ref-info>
<ref-fulltext>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ref-fulltext>
<ce:source-text>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Protein, glucose and lipid metabolism in the cancer cachexia: a preliminary report [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R..</ce:initials>
<ce:surname>Dodesini</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Benedini</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Terruzzi</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
</ref-info>
<ref-fulltext>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: a preliminary report [1]. Acta Oncol. (2007)</ref-fulltext>
<ce:source-text>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: a preliminary report [1]. Acta Oncol. (2007)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Diabetes and altered carbohydrate metabolism in patients with cancer </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Glicksman</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Rawson</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1956"/>
</ref-info>
<ref-fulltext>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/ 12)9:63.0.CO;2-4</ref-fulltext>
<ce:source-text>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/ 12)9:63.0.CO;2-4</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Sugar tolerance in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.L.</ce:initials>
<ce:surname>Rohdenburg</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bernhard</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Krehbiel</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Med. Assoc</ref-sourcetitle>
<ref-publicationyear first="1919"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1001/jama.1919.02610210024007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ref-fulltext>
<ce:source-text>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>A review of cancer cachexia and abnormal glucose metabolism in humans with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Tayek</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Coll. Nutr</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10. 1080/07315724.1992.10718249</ce:e-address> </ref-website>
</ref-info>
<ref-fulltext>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10. 1080/07315724.1992.10718249</ref-fulltext>
<ce:source-text>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10. 1080/07315724.1992.10718249</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Asp</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Wendel</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Belury</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.24784</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ref-fulltext>
<ce:source-text>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.C.</ce:initials>
<ce:surname>Fontes-Oliveira</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
</ref-info>
<ref-fulltext>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ref-fulltext>
<ce:source-text>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated energy expenditure in cancer patients with solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hyltander</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Drott</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Körner</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0277-5379(91)90050-N</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ref-fulltext>
<ce:source-text>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia, mechanism and treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Aoyagi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.P.</ce:initials>
<ce:surname>Terracina</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raza</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J. Gastrointest. Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4251/wjgo.v7.i4.17</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ref-fulltext>
<ce:source-text>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Faber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Uitdehaag</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Spaander</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ref-fulltext>
<ce:source-text>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Leśniak</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Bała</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Jaeschke</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Krzakowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Polskie Archiwum Medycyny Wewnetrznej</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.20452/pamw.510</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ref-fulltext>
<ce:source-text>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.P.</ce:initials>
<ce:surname>López</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Roqué I Figuls</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.U.</ce:initials>
<ce:surname>Cuchi</ce:surname>
<ce:given-name>G.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Sympt. Manag</ref-sourcetitle>
<ref-publicationyear first="2004"/>
</ref-info>
<ref-fulltext>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ref-fulltext>
<ce:source-text>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Megestrol acetate for treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.R.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>Ruiz</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>López-Briz</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.C.</ce:initials>
<ce:surname>Sanchis</ce:surname>
<ce:given-name>Carbonell</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cochrane Database Syst. Rev</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ref-fulltext>
<ce:source-text>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of the treatment of cancer-associated anorexia and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tugba</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.P.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Declan</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8500</first-page>
<last-page>8511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ref-fulltext>
<ce:source-text>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Progesterone therapy for the treatment of non-cancer cachexia: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.P.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Pendleton</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ref-fulltext>
<ce:source-text>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lecker</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>39</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.03-0610com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ref-fulltext>
<ce:source-text>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Hyatt</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-6604com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ref-fulltext>
<ce:source-text>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 controls autophagy in skeletal muscle in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Mammucari</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Romanello</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>458</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ref-fulltext>
<ce:source-text>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation and involvement of the ubiquitin ligases in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Free Radic. Biol. Med</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ref-fulltext>
<ce:source-text>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schild</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.11.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ref-fulltext>
<ce:source-text>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.G.</ce:initials>
<ce:surname>Jespersen</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19460</first-page>
<last-page>19471</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M110.113092</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ref-fulltext>
<ce:source-text>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Handschin</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0607795103</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ref-fulltext>
<ce:source-text>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Masiero</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>191</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>101</first-page>
<last-page>113</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201001136</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ref-fulltext>
<ce:source-text>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M113.489716</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ref-fulltext>
<ce:source-text>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>PI3 kinase regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Top. Microbiol. Immunol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/82-2010-78</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ref-fulltext>
<ce:source-text>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Role and regulation of starvation-induced autophagy in the Drosophila fat body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Schuldiner</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.P.</ce:initials>
<ce:surname>Neufeld</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.devcel.2004.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ref-fulltext>
<ce:source-text>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.R.</ce:initials>
<ce:surname>Amini</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Amini</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M407517200</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ref-fulltext>
<ce:source-text>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Shimizu</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Yoshikawa</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Ito</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2011.01.001</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ref-fulltext>
<ce:source-text>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/en.2006-0251</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ref-fulltext>
<ce:source-text>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Watts</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>McAinch</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Obesity</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20070</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ref-fulltext>
<ce:source-text>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Devivo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.H.R.</ce:initials>
<ce:surname>Hoyle</ce:surname>
<ce:given-name>D.H.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ref-fulltext>
<ce:source-text>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ballarò</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Martinez-Cristobal</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.jmb.2019.05.032</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ref-fulltext>
<ce:source-text>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2015.3845</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ref-fulltext>
<ce:source-text>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of ubiquitin ligases required for skeletal Muscle Atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Bodine</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Baumhueter</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1065874</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ref-fulltext>
<ce:source-text>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in disease: Molecular mechanisms and promising therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nathan</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>58</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrd4467</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ref-fulltext>
<ce:source-text>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.K.R.</ce:initials>
<ce:surname>Mukkamalla</ce:surname>
<ce:given-name>S.K.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Calderon</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Med. Pract</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ref-fulltext>
<ce:source-text>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.W.</ce:initials>
<ce:surname>Grandin</ce:surname>
<ce:given-name>E.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Ky</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.F.</ce:initials>
<ce:surname>Cornell</ce:surname>
<ce:given-name>R.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Card. Fail</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cardfail.2014.11.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ref-fulltext>
<ce:source-text>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hacihanefioglu</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Tarkun</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Gonullu</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Hematol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s12185-008-0139-7</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ref-fulltext>
<ce:source-text>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Primary proteasome inhibition results in cardiac dysfunction. Eur. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Herrmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Wohlert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Saguner</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hft034</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ref-fulltext>
<ce:source-text>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Jorge</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Patricia</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Asaf</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ref-fulltext>
<ce:source-text>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib-induced severe congestive heart failure</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Jerkins</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiol. Res</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4021/cr105e</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ref-fulltext>
<ce:source-text>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>Unexpected cardiotoxicity in haematological bortezomib treated patients [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Orciuolo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gabriele</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Cecconi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Haematol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
</ref-info>
<ref-fulltext>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ref-fulltext>
<ce:source-text>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Takakuwa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Otomaru</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Araki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Case Reports Hematol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2019/1816287</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ref-fulltext>
<ce:source-text>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Voortman</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Giaccone</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2407-6-129</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ref-fulltext>
<ce:source-text>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12050</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ref-fulltext>
<ce:source-text>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Res. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s00432-013-1412-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ref-fulltext>
<ce:source-text>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Bowen</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Adams</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Werner</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12233</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ref-fulltext>
<ce:source-text>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Cong</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Tien</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Gene Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1089/hum.2010.057</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ref-fulltext>
<ce:source-text>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wada</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kato</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Okutsu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M111.271270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ref-fulltext>
<ce:source-text>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Klaude</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Fredriksson</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Tjäder</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20060265</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ref-fulltext>
<ce:source-text>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hobler</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI119143</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ref-fulltext>
<ce:source-text>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Llovera</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Garcia-Martinez</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Agell</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/ijmm.2.1.69</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ref-fulltext>
<ce:source-text>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.T.</ce:initials>
<ce:surname>de Castro</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Östling</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00110.2014</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ref-fulltext>
<ce:source-text>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Suetta</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Frandsen</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0051238</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ref-fulltext>
<ce:source-text>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.T.</ce:initials>
<ce:surname>Langer</ce:surname>
<ce:given-name>H.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.G.</ce:initials>
<ce:surname>Senden</ce:surname>
<ce:given-name>J.M.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Gijsen</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2018.01220</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ref-fulltext>
<ce:source-text>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle proteasome activity correlates with disease severity in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle ubiquitin mrna levels in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.H.C.</ce:initials>
<ce:surname>Dejong</ce:surname>
<ce:given-name>C.H.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.14.1.257</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ref-fulltext>
<ce:source-text>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.V.</ce:initials>
<ce:surname>Hine</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2004.10.017</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ref-fulltext>
<ce:source-text>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.S.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>Y.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Qian</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Can</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1756-9966-31-81</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ref-fulltext>
<ce:source-text>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.E.</ce:initials>
<ce:surname>Fischer</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.O.</ce:initials>
<ce:surname>Hasselgren</ce:surname>
<ce:given-name>P.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/S0039-6060(99)70131-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ref-fulltext>
<ce:source-text>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Aniort</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Stella</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Philipponnet</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12376</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ref-fulltext>
<ce:source-text>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.P.F.</ce:initials>
<ce:surname>Redfern</ce:surname>
<ce:given-name>C.P.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Roberts</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20010270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ref-fulltext>
<ce:source-text>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Op Den Kamp</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>Langen</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Minnaard</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2011.09.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ref-fulltext>
<ce:source-text>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Murton</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Maddocks</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.B.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>F.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cllc.2016.06.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ref-fulltext>
<ce:source-text>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Okamoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Torii</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Machida</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol. Sci</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ref-fulltext>
<ce:source-text>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Breakdown of filamentous myofibrils by the UPS-step by step</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomol. Ther</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/biom11010110</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ref-fulltext>
<ce:source-text>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Rudesky</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>217</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3698</first-page>
<last-page>3714</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201802018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ref-fulltext>
<ce:source-text>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200901052</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ref-fulltext>
<ce:source-text>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>575</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201110067</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ref-fulltext>
<ce:source-text>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Kosti</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1612988114</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ref-fulltext>
<ce:source-text>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Costamagna</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ajpath.2012.12.023</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ref-fulltext>
<ce:source-text>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lucia</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/srep30340</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ref-fulltext>
<ce:source-text>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-02088-2</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Striated muscle cytoarchitecture: An intricate web of form and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Clark</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>McElhinny</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.C.</ce:initials>
<ce:surname>Beckerle</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ref-fulltext>
<ce:source-text>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiovasc. Res</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/cvr/cvn073</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ref-fulltext>
<ce:source-text>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Rottbauer</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Wessels</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ref-fulltext>
<ce:source-text>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle myosin light chains are essential for physiological speeds of shortening</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lowey</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.S.</ce:initials>
<ce:surname>Waller</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.M.</ce:initials>
<ce:surname>Trybus</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/365454a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ref-fulltext>
<ce:source-text>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle myosin light chains are essential for physiological speeds of shortening</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lowey</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.S.</ce:initials>
<ce:surname>Waller</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.M.</ce:initials>
<ce:surname>Trybus</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/365454a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ref-fulltext>
<ce:source-text>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of monomeric and polymeric actin with myosin subfragment 1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Offer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Baker</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Baker</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="1972"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0022-2836(72)90425-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ref-fulltext>
<ce:source-text>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Sanbe</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Osinska</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI3880</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ref-fulltext>
<ce:source-text>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Paulin</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
</ref-info>
<ref-fulltext>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ref-fulltext>
<ce:source-text>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.S.</ce:initials>
<ce:surname>Willis</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>376</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.09.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ref-fulltext>
<ce:source-text>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Novel TRIM32 mutation in sarcotubular myopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Panicucci</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Traverso</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Baratto</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Myologica</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ref-fulltext>
<ce:source-text>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Cécile</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Anne-Elisabeth</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Marianne</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3790</first-page>
<last-page>3802</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/FJ.11-180968</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ref-fulltext>
<ce:source-text>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.-M.</ce:initials>
<ce:surname>Dulce</ce:surname>
<ce:given-name>P.-M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Mélodie</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Agnès</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/CELLS10081974</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ref-fulltext>
<ce:source-text>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Antonioli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Fusco</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Adv</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/sciadv.aau8857</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ref-fulltext>
<ce:source-text>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Piacentini</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fimia</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ref-fulltext>
<ce:source-text>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>412</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/S0092867404004003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ref-fulltext>
<ce:source-text>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/emboj.2012.178</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ref-fulltext>
<ce:source-text>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Remodeling of the cytoskeletal lattice in denervated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Boudriau</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.H.</ce:initials>
<ce:surname>Côté</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Vincent</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ref-fulltext>
<ce:source-text>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Role of calpains in promoting desmin filaments depolymerization and muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochim. Biophys. Acta Mol. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>1867</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbamcr.2020.118788</ce:e-address>
</ref-website>
<ref-text>118788</ref-text>
</ref-info>
<ref-fulltext>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ref-fulltext>
<ce:source-text>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="1978"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0014-4827(78)90209-4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ref-fulltext>
<ce:source-text>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Immunological characterization of the subunit of the 100 Å filaments from muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.D.</ce:initials>
<ce:surname>Hubbard</ce:surname>
<ce:given-name>B.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1976"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.73.12.4344</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ref-fulltext>
<ce:source-text>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of muscle architecture and myocardial degeneration in mice lacking desmin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Milner</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Weitzer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Tran</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.134.5.1255</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ref-fulltext>
<ce:source-text>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Conover</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.N.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>S.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1091/mbc.E08-07-0753</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ref-fulltext>
<ce:source-text>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.Y.</ce:initials>
<ce:surname>Shum</ce:surname>
<ce:given-name>A.M.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Poljak</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.L.</ce:initials>
<ce:surname>Bentley</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.18632/oncotarget.25146</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ref-fulltext>
<ce:source-text>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.R.</ce:initials>
<ce:surname>Helliwell</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Gunhan</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.H.T.</ce:initials>
<ce:surname>Edwards</ce:surname>
<ce:given-name>R.H.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pathol</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/path.1711590111</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ref-fulltext>
<ce:source-text>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>New roles for desmin in maintenance of muscle homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Agnetti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Herrmann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FEBS J</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>15864</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/febs.15864</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ref-fulltext>
<ce:source-text>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Evenson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.U.</ce:initials>
<ce:surname>Fareed</ce:surname>
<ce:given-name>M.U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Menconi</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.06.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ref-fulltext>
<ce:source-text>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.P.</ce:initials>
<ce:surname>Verhees</ce:surname>
<ce:given-name>K.J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.M.W.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.C.J.M.</ce:initials>
<ce:surname>Kelders</ce:surname>
<ce:given-name>M.C.J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00520.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ref-fulltext>
<ce:source-text>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.E.</ce:initials>
<ce:surname>Cross</ce:surname>
<ce:given-name>D.A.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Alessi</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/378785a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ref-fulltext>
<ce:source-text>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Measuring GSK3 expression and activity in cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Cole</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Methods Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/978-1-59745-249-6_4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ref-fulltext>
<ce:source-text>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>What are the bona fide GSK3 substrates?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Alzheimer’s Dis</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ref-fulltext>
<ce:source-text>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.Y.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.Z.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>S.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2017.5396</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ref-fulltext>
<ce:source-text>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.G.</ce:initials>
<ce:surname>Minero</ce:surname>
<ce:given-name>V.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2017.00213</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ref-fulltext>
<ce:source-text>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ce:source-text>
</reference>
<reference seq="232">
<ref-info>
<ref-title>
<ref-titletext-english>A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Eid Mutlak</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1381</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41467-020-14895-9</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ref-fulltext>
<ce:source-text>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ce:source-text>
</reference>
<reference seq="233">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Lapidos</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kakkar</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.M.</ce:initials>
<ce:surname>McNally</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1023</first-page>
<last-page>1031</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ref-fulltext>
<ce:source-text>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:source-text>
</reference>
<reference seq="234">
<ref-info>
<ref-title>
<ref-titletext-english>The costamere bridges sarcomeres to the sarcolemma in striated muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Peter</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.S.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Prog. Pediatr. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ref-fulltext>
<ce:source-text>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:source-text>
</reference>
<reference seq="235">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane organization of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ervasti</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.P.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(91)90035-W</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ref-fulltext>
<ce:source-text>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ce:source-text>
</reference>
<reference seq="236">
<ref-info>
<ref-title>
<ref-titletext-english>Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Madhavan</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.R.</ce:initials>
<ce:surname>Massom</ce:surname>
<ce:given-name>L.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0006-291X(92)91690-R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ref-fulltext>
<ce:source-text>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ce:source-text>
</reference>
<reference seq="237">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1575</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.1192</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ref-fulltext>
<ce:source-text>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ce:source-text>
</reference>
<reference seq="238">
<ref-info>
<ref-title>
<ref-titletext-english>Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Ramaswamy</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.L.</ce:initials>
<ce:surname>Palmer</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.H.</ce:initials>
<ce:surname>Van der Meulen</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>589</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1195</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1113/jphysiol.2010.201921</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ref-fulltext>
<ce:source-text>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ce:source-text>
</reference>
<reference seq="239">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex in the prevention of muscle damage</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Gumerson</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.E.</ce:initials>
<ce:surname>Michele</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biomed. Biotechnol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ref-fulltext>
<ce:source-text>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ce:source-text>
</reference>
<reference seq="240">
<ref-info>
<ref-title>
<ref-titletext-english>Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Claflin</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00244.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ref-fulltext>
<ce:source-text>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ce:source-text>
</reference>
<reference seq="241">
<ref-info>
<ref-title>
<ref-titletext-english>Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dellorusso</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Crawford</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.S.</ce:initials>
<ce:surname>Chamberlain</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Muscle Res. Cell Motil</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1023/A:1014587918367</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ref-fulltext>
<ce:source-text>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ce:source-text>
</reference>
<reference seq="242">
<ref-info>
<ref-title>
<ref-titletext-english>A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Kimura</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Ng</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Mol. Genet</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/hmg/ddl082</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ref-fulltext>
<ce:source-text>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ce:source-text>
</reference>
<reference seq="243">
<ref-info>
<ref-title>
<ref-titletext-english>The extracellular matrix protein agrin promotes heart regeneration in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Bassat</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.E.</ce:initials>
<ce:surname>Mutlak</ce:surname>
<ce:given-name>Y.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Genzelinakh</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>184</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nature22978</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ref-fulltext>
<ce:source-text>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ce:source-text>
</reference>
<reference seq="244">
<ref-info>
<ref-title>
<ref-titletext-english>The molecular cross talk of the dystrophin–glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gawor</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.J.</ce:initials>
<ce:surname>Prószyński</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. NY Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ref-fulltext>
<ce:source-text>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ce:source-text>
</reference>
<reference seq="245">
<ref-info>
<ref-title>
<ref-titletext-english>Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Yatsenko</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.M.</ce:initials>
<ce:surname>Kucherenko</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Med</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/s12916-019-1478-3</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ref-fulltext>
<ce:source-text>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ce:source-text>
</reference>
<reference seq="246">
<ref-info>
<ref-title>
<ref-titletext-english>Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Anderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.P.</ce:initials>
<ce:surname>Rogers</ce:surname>
<ce:given-name>R.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.271.12.6605</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ref-fulltext>
<ce:source-text>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ce:source-text>
</reference>
<reference seq="247">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.D.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yue</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI36612</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ref-fulltext>
<ce:source-text>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ce:source-text>
</reference>
<reference seq="248">
<ref-info>
<ref-title>
<ref-titletext-english>Mouse α1-syntrophin binding to Grb2: Further evidence of a role for syntrophin in cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Oak</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Russo</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.C.</ce:initials>
<ce:surname>Petrucci</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochemistry</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1021/bi010490n</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ref-fulltext>
<ce:source-text>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ce:source-text>
</reference>
<reference seq="249">
<ref-info>
<ref-title>
<ref-titletext-english>SH3 domain-mediated interaction of dystroglycan and Grb2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Motto</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.270.20.11711</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ref-fulltext>
<ce:source-text>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ce:source-text>
</reference>
<reference seq="250">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>Langenbach</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.10258</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ref-fulltext>
<ce:source-text>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ce:source-text>
</reference>
<reference seq="251">
<ref-info>
<ref-title>
<ref-titletext-english>Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>204</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>747</first-page>
<last-page>758</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201304167</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ref-fulltext>
<ce:source-text>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ce:source-text>
</reference>
<reference seq="252">
<ref-info>
<ref-title>
<ref-titletext-english>Muscular dystrophies at different ages: Metabolic and endocrine alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.D.R.</ce:initials>
<ce:surname>Cruz Guzmán</ce:surname>
<ce:given-name>O.D.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Chávez García</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rodríguez-Cruz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="253">
<ref-info>
<ref-title>
<ref-titletext-english>Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Freidenberg</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Olefsky</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jcem-60-2-320</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ref-fulltext>
<ce:source-text>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ce:source-text>
</reference>
<reference seq="254">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rodriguez-Cruz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.E.</ce:initials>
<ce:surname>Escobar</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2015/867273</ce:e-address>
</ref-website>
<ref-text>867273</ref-text>
</ref-info>
<ref-fulltext>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ref-fulltext>
<ce:source-text>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ce:source-text>
</reference>
<reference seq="255">
<ref-info>
<ref-title>
<ref-titletext-english>iLIR database: A web resource for LIR motif-containing proteins in eukaryotes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Jacomin</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Samavedam</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Promponas</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.P.</ce:initials>
<ce:surname>Nezis</ce:surname>
<ce:given-name>I.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1945</first-page>
<last-page>1953</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1080/15548627.2016.1207016</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ref-fulltext>
<ce:source-text>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ce:source-text>
</reference>
<reference seq="256">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle hypertrophy and atrophy signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1974</first-page>
<last-page>1984</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.04.018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ref-fulltext>
<ce:source-text>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ce:source-text>
</reference>
<reference seq="257">
<ref-info>
<ref-title>
<ref-titletext-english>IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Ohtsuka</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.C.</ce:initials>
<ce:surname>McLary</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00073.2004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ref-fulltext>
<ce:source-text>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ce:source-text>
</reference>
<reference seq="258">
<ref-info>
<ref-title>
<ref-titletext-english>The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.N.</ce:initials>
<ce:surname>Stitt</ce:surname>
<ce:given-name>T.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ref-fulltext>
<ce:source-text>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ce:source-text>
</reference>
<reference seq="259">
<ref-info>
<ref-title>
<ref-titletext-english>The LIR motif – crucial for selective autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Å.B.</ce:initials>
<ce:surname>Birgisdottir</ce:surname>
<ce:given-name>Å.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Lamark</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Johansen</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Sci</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1242/jcs.126128</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ref-fulltext>
<ce:source-text>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ce:source-text>
</reference>
<reference seq="260">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical trials of cancer cachexia therapy, now and hereafter</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ref-fulltext>
<ce:source-text>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ce:source-text>
</reference>
<reference seq="261">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.C.</ce:initials>
<ce:surname>Mueller</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Prokopchuk</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ref-fulltext>
<ce:source-text>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_6</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Cytokines</author-keyword>
<author-keyword>Cancer</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Wasting</author-keyword>
<author-keyword>GP130</author-keyword>
<author-keyword>JAK/STAT</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">The Role of Interleukin-6/GP130 Cytokines in Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>D.H.A.</ce:initials> 
<ce:surname>Jengelley</ce:surname>
<ce:given-name>Daenique H. A</ce:given-name>
</author>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<state>Indianapolis</state>
<country iso-code="USA"/>
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>T.A.</ce:initials> 
<ce:surname>Zimmers</ce:surname>
<ce:given-name>Teresa A.</ce:given-name>
</author>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<organization>Department of Surgery</organization>
<organization>Department of Otolaryngology—Head &amp; Neck Surgery</organization>
<state>Indianapolis</state>
<country iso-code="USA"/>
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA Department of Surgery, Indianapolis, IN, USA Department of Anatomy, Cell Biology, &amp; Physiology, Indianapolis, IN, USA Department of Otolaryngology—Head &amp; Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Research Service, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indianapolis, IN, USA Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>T.A.</ce:initials> 
<ce:surname>Zimmers</ce:surname>
<ce:given-name>Teresa A.</ce:given-name>
<ce:e-address>zimmerst@iu.edu</ce:e-address>
</person>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<organization>Department of Surgery</organization>
<organization>Department of Otolaryngology—Head &amp; Neck Surgery</organization>
<state>Indianapolis</state>
<country iso-code="USA"/>
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA Department of Surgery, Indianapolis, IN, USA Department of Anatomy, Cell Biology, &amp; Physiology, Indianapolis, IN, USA Department of Otolaryngology—Head &amp; Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Research Service, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indianapolis, IN, USA Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cancer cachexia is characterized by the invol- untary loss of skeletal muscle with or without adipose tissue loss in the presence of tumor burden. It is a prevalent yet clinically unmet need that results in devastating systemic wasting effects. Chronic inflammation triggers cancer progression and is observed in cachexia. This review will highlight the Interleukin-6 (IL-6) family of cytokines, including IL-6 itself, Leukemia Inhibitory Fac- tor (LIF), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin-1 (CT-1), Oncostatin M (OSM), Interleukin-11 (IL-11), Interleukin-27 (IL-27), and Cardiotrophin- like cytokine (CLC), which all share signaling through IL-6 Signal Transducer (IL6ST), also known as Glycoprotein 130 (GP130) to acti- vate common downstream pathways including the JAK/STAT, MAPK, and AKT pathways. IL-6 has been long linked to cancer cachexia through both associative and functional stud- ies; furthermore, anti-IL-6 therapies have been trialed in patients. Recently, LIF has emerged as a novel cachexia mediator in experimental systems. Far less is known about the other cytokines in cachexia, although they have sug- gestive properties on adipose and muscle tissues in other contexts. Future studies are required to determine the roles of these other factors in cancer cachexia and their potential for designing therapies.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">978-3-031-07272-7</isbn>
<isbn type="electronic" length="13">978-3-031-09518-4</isbn>
<volisspag>
<page-information>
<pages>
<first-page>97</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="240">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is defined by an ongoing loss of skeletal muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.S.</ce:initials>
<ce:surname>Bhullar</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann Palliat Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Mazurak, V.C., Bhullar, A.S.: Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 8(1), 3–12 (2019)</ref-fulltext>
<ce:source-text>Baracos, V.E., Mazurak, V.C., Bhullar, A.S.: Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 8(1), 3–12 (2019)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1012</first-page>
<last-page>1019</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Prado, C.M., et al.: Tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am. J. Clin. Nutr. 98(4), 1012–1019 (2013)</ref-fulltext>
<ce:source-text>Prado, C.M., et al.: Tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am. J. Clin. Nutr. 98(4), 1012–1019 (2013)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenic obesity: Hidden muscle wasting and its impact for survival and complications of cancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Arribas</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Arribas, L.: Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29, ii1–ii9 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Arribas, L.: Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29, ii1–ii9 (2018)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia, mechanism and treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Aoyagi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J Gastrointest Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aoyagi, T., et al.: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7(4), 17–29 (2015)</ref-fulltext>
<ce:source-text>Aoyagi, T., et al.: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7(4), 17–29 (2015)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia and related metabolic dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Fonseca</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fonseca, G., et al.: Cancer cachexia and related metabolic dysfunction. Int. J. Mol. Sci. 21(7) (2020)</ref-fulltext>
<ce:source-text>Fonseca, G., et al.: Cancer cachexia and related metabolic dysfunction. Int. J. Mol. Sci. 21(7) (2020)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the mechanisms and treatment options in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>99</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Arends, J., Baracos, V.: Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10(2), 90–99 (2013)</ref-fulltext>
<ce:source-text>Fearon, K., Arends, J., Baracos, V.: Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10(2), 90–99 (2013)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5, e200 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5, e200 (2016)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Principles of interleukin (IL)-6-type cytokine signalling and its regulation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Heinrich</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. J</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>374</vol-first>
<part>Part 1</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>20</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heinrich, P.C., et al.: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1–20 (2003)</ref-fulltext>
<ce:source-text>Heinrich, P.C., et al.: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1–20 (2003)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>ER stress and unfolded protein response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Roy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Roy, A., Kumar, A.: ER stress and unfolded protein response in cancer cachexia. Cancers (Basel). 11(12) (2019)</ref-fulltext>
<ce:source-text>Roy, A., Kumar, A.: ER stress and unfolded protein response in cancer cachexia. Cancers (Basel). 11(12) (2019)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.N.</ce:initials>
<ce:surname>Langstein</ce:surname>
<ce:given-name>H.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Norton</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hematol. Oncol. Clin. North A</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>103</first-page>
<last-page>123</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Langstein, H.N., Norton, J.A.: Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5(1), 103–123 (1991)</ref-fulltext>
<ce:source-text>Langstein, H.N., Norton, J.A.: Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5(1), 103–123 (1991)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Catabolic mediators of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>256</first-page>
<last-page>261</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care. 2(4), 256–261 (2008)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care. 2(4), 256–261 (2008)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 in the systemic inflammation of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.L.</ce:initials>
<ce:surname>Fishel</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28</first-page>
<last-page>41</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zimmers, T.A., Fishel, M.L., Bonetto, A.: STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28–41 (2016)</ref-fulltext>
<ce:source-text>Zimmers, T.A., Fishel, M.L., Bonetto, A.: STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28–41 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.B</ce:initials>
<ce:surname>Klimek</ce:surname>
<ce:given-name>Benny</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNA in cancer and cachexia – a mini-review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Acunzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Croce</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Infect. Dis</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
<suppl>Supplement 1</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Acunzo, M., Croce, C.M.: MicroRNA in cancer and cachexia – a mini-review. J. Infect. Dis. 212(Suppl 1), S74–S77 (2015)</ref-fulltext>
<ce:source-text>Acunzo, M., Croce, C.M.: MicroRNA in cancer and cachexia – a mini-review. J. Infect. Dis. 212(Suppl 1), S74–S77 (2015)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(1), 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(1), 589 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Michaelis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4682</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Michaelis, K.A., et al.: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10(1), 4682 (2019)</ref-fulltext>
<ce:source-text>Michaelis, K.A., et al.: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10(1), 4682 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argilés, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>420</vol-first>
<iss-first>6917</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>867</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coussens, L.M., Werb, Z.: Inflammation and cancer. Nature. 420(6917), 860–867 (2002)</ref-fulltext>
<ce:source-text>Coussens, L.M., Werb, Z.: Inflammation and cancer. Nature. 420(6917), 860–867 (2002)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Singh</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Afr. Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>121</first-page>
<last-page>126</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Singh, N., et al.: Inflammation and cancer. Ann. Afr. Med. 18(3), 121–126 (2019)</ref-fulltext>
<ce:source-text>Singh, N., et al.: Inflammation and cancer. Ann. Afr. Med. 18(3), 121–126 (2019)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Coordination of immune-stroma crosstalk by IL-6 family cytokines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.R.</ce:initials>
<ce:surname>West</ce:surname>
<ce:given-name>N.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1093</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>West, N.R.: Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019)</ref-fulltext>
<ce:source-text>West, N.R.: Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>The gp130 receptor cytokine family: Regulators of adipocyte development and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.A.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>U.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Des</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>346</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, U.A., Stephens, J.M.: The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 17(4), 340–346 (2011)</ref-fulltext>
<ce:source-text>White, U.A., Stephens, J.M.: The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 17(4), 340–346 (2011)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 family cytokines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rose-John</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rose-John, S.: Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10(2) (2018)</ref-fulltext>
<ce:source-text>Rose-John, S.: Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10(2) (2018)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2839</first-page>
<last-page>2848</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 10(10), 2839–2848 (1991)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 10(10), 2839–2848 (1991)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Pennica</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>270</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10915</first-page>
<last-page>10922</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pennica, D., et al.: Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270(18), 10915–10922 (1995)</ref-fulltext>
<ce:source-text>Pennica, D., et al.: Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270(18), 10915–10922 (1995)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>255</vol-first>
<iss-first>5050</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1434</first-page>
<last-page>1437</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science. 255(5050), 1434–1437 (1992)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science. 255(5050), 1434–1437 (1992)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ichihara</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>165</first-page>
<last-page>173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ichihara, M., et al.: Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 90(1), 165–173 (1997)</ref-fulltext>
<ce:source-text>Ichihara, M., et al.: Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 90(1), 165–173 (1997)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.M.</ce:initials>
<ce:surname>Hermanns</ce:surname>
<ce:given-name>H.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>545</first-page>
<last-page>558</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hermanns, H.M.: Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26(5), 545–558 (2015)</ref-fulltext>
<ce:source-text>Hermanns, H.M.: Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26(5), 545–558 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Mosley</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32635</first-page>
<last-page>32643</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mosley, B., et al.: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271(51), 32635–32643 (1996)</ref-fulltext>
<ce:source-text>Mosley, B., et al.: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271(51), 32635–32643 (1996)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<volisspag>
<volume-issue-number>
<vol-first>260</vol-first>
<iss-first>5115</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1805</first-page>
<last-page>1808</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Davis, S., et al.: LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260(5115), 1805–1808 (1993)</ref-fulltext>
<ce:source-text>Davis, S., et al.: LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260(5115), 1805–1808 (1993)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.C.</ce:initials>
<ce:surname>Elson</ce:surname>
<ce:given-name>G.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>867</first-page>
<last-page>872</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elson, G.C., et al.: CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3(9), 867–872 (2000)</ref-fulltext>
<ce:source-text>Elson, G.C., et al.: CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3(9), 867–872 (2000)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.</ce:initials>
<ce:surname>Jenkins</ce:surname>
<ce:given-name>B.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>773</first-page>
<last-page>789</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jones, S.A., Jenkins, B.J.: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18(12), 773–789 (2018)</ref-fulltext>
<ce:source-text>Jones, S.A., Jenkins, B.J.: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18(12), 773–789 (2018)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 in inflammation, immunity, and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Narazaki</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Kishimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Tanaka, T., Narazaki, M., Kishimoto, T.: IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6(10), a016295 (2014)</ref-fulltext>
<ce:source-text>Tanaka, T., Narazaki, M., Kishimoto, T.: IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6(10), a016295 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Factors affecting B-cell growth and differentiation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Kishimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kishimoto, T.: Factors affecting B-cell growth and differentiation. Annu. Rev. Immunol. 3, 133–157 (1985)</ref-fulltext>
<ce:source-text>Kishimoto, T.: Factors affecting B-cell growth and differentiation. Annu. Rev. Immunol. 3, 133–157 (1985)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and the acute phase response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Heinrich</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Castell</ce:surname>
<ce:given-name>J.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Andus</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. J</ref-sourcetitle>
<ref-publicationyear first="1990"/>
<volisspag>
<volume-issue-number>
<vol-first>265</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>621</first-page>
<last-page>636</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heinrich, P.C., Castell, J.V., Andus, T.: Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621–636 (1990)</ref-fulltext>
<ce:source-text>Heinrich, P.C., Castell, J.V., Andus, T.: Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621–636 (1990)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.E.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>O’Keefe</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Grandis</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>248</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnson, D.E., O’Keefe, R.A., Grandis, J.R.: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15(4), 234–248 (2018)</ref-fulltext>
<ce:source-text>Johnson, D.E., O’Keefe, R.A., Grandis, J.R.: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15(4), 234–248 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is a potent thrombopoietic factor in vivo in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ishibashi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1241</first-page>
<last-page>1244</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ishibashi, T., et al.: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74(4), 1241–1244 (1989)</ref-fulltext>
<ce:source-text>Ishibashi, T., et al.: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74(4), 1241–1244 (1989)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Miyamoto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3999</first-page>
<last-page>4004</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miyamoto, Y., et al.: Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment. Clin. Cancer Res. 22(16), 3999–4004 (2016)</ref-fulltext>
<ce:source-text>Miyamoto, Y., et al.: Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment. Clin. Cancer Res. 22(16), 3999–4004 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>190</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>415</first-page>
<last-page>423</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, C.H., et al.: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J. Endocrinol. 190(2), 415–423 (2006)</ref-fulltext>
<ce:source-text>Wang, C.H., et al.: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J. Endocrinol. 190(2), 415–423 (2006)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rose-John</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biol. Sci</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1237</first-page>
<last-page>1247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rose-John, S.: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8(9), 1237–1247 (2012)</ref-fulltext>
<ce:source-text>Rose-John, S.: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8(9), 1237–1247 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.E.</ce:initials>
<ce:surname>Barton</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.F.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>T.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>251</first-page>
<last-page>257</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barton, B.E., Murphy, T.F.: Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 16(6), 251–257 (2001)</ref-fulltext>
<ce:source-text>Barton, B.E., Murphy, T.F.: Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 16(6), 251–257 (2001)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Tamura</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1353</first-page>
<last-page>1358</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tamura, S., et al.: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res. 1(11), 1353–1358 (1995)</ref-fulltext>
<ce:source-text>Tamura, S., et al.: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res. 1(11), 1353–1358 (1995)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Vis. Exp</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<vol-first>117</vol-first>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence for the involvement of interleukin 6 in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Strassmann</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1681</first-page>
<last-page>1684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Strassmann, G., et al.: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89(5), 1681–1684 (1992)</ref-fulltext>
<ce:source-text>Strassmann, G., et al.: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89(5), 1681–1684 (1992)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 as a key regulator of muscle mass during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exerc. Sport Sci. Rev</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>168</first-page>
<last-page>176</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 38(4), 168–176 (2010)</ref-fulltext>
<ce:source-text>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 38(4), 168–176 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.F.</ce:initials>
<ce:surname>Ouchi</ce:surname>
<ce:given-name>Fujimoto</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>56</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>807</first-page>
<last-page>815</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fujimoto-Ouchi, K., et al.: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother. Pharmacol. 59(6), 807–815 (2007)</ref-fulltext>
<ce:source-text>Fujimoto-Ouchi, K., et al.: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother. Pharmacol. 59(6), 807–815 (2007)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303(3), E410–E421 (2012)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303(3), E410–E421 (2012)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.F.</ce:initials>
<ce:surname>Ouchi</ce:surname>
<ce:given-name>Fujimoto</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>522</first-page>
<last-page>528</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fujimoto-Ouchi, K., et al.: Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer. 61(4), 522–528 (1995)</ref-fulltext>
<ce:source-text>Fujimoto-Ouchi, K., et al.: Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer. 61(4), 522–528 (1995)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor inoculation site affects the development of cancer cachexia and muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Matsuyama</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>137</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2558</first-page>
<last-page>2565</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matsuyama, T., et al.: Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int. J. Cancer. 137(11), 2558–2565 (2015)</ref-fulltext>
<ce:source-text>Matsuyama, T., et al.: Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int. J. Cancer. 137(11), 2558–2565 (2015)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Mehl</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. (1985)</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2379</first-page>
<last-page>2387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mehl, K.A., et al.: Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J. Appl. Physiol. (1985), 2005. 99(6): 2379–2387</ref-fulltext>
<ce:source-text>Mehl, K.A., et al.: Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J. Appl. Physiol. (1985), 2005. 99(6): 2379–2387</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Onuma</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>116</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>478</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Onuma, E., et al.: Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int. J. Cancer. 116(3), 471–478 (2005)</ref-fulltext>
<ce:source-text>Onuma, E., et al.: Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int. J. Cancer. 116(3), 471–478 (2005)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Iguchi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>27</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iguchi, H., et al.: Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int. J. Cancer. 94(1), 24–27 (2001)</ref-fulltext>
<ce:source-text>Iguchi, H., et al.: Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int. J. Cancer. 94(1), 24–27 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.H.</ce:initials>
<ce:surname>Zaki</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nemeth</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Trikha</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>592</first-page>
<last-page>595</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zaki, M.H., Nemeth, J.A., Trikha, M.: CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111(4), 592–595 (2004)</ref-fulltext>
<ce:source-text>Zaki, M.H., Nemeth, J.A., Trikha, M.: CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111(4), 592–595 (2004)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.R.</ce:initials>
<ce:surname>Flint</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>672</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Flint, T.R., et al.: Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24(5), 672–684 (2016)</ref-fulltext>
<ce:source-text>Flint, T.R., et al.: Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24(5), 672–684 (2016)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Rupert</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>218</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rupert, J.E., et al.: Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218(6), e20190450 (2021)</ref-fulltext>
<ce:source-text>Rupert, J.E., et al.: Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218(6), e20190450 (2021)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Negri</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>27</first-page>
<last-page>38</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Negri, D.R., et al.: Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 15(1), 27–38 (2001)</ref-fulltext>
<ce:source-text>Negri, D.R., et al.: Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 15(1), 27–38 (2001)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and cachexia in ApcMin/+ mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Baltgalvis, K.A., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294(2), R393–R401 (2008)</ref-fulltext>
<ce:source-text>Baltgalvis, K.A., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294(2), R393–R401 (2008)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Complement Med Ther</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, S., et al.: Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model. BMC Complement Med Ther. 20(1), 11 (2020)</ref-fulltext>
<ce:source-text>Lu, S., et al.: Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model. BMC Complement Med Ther. 20(1), 11 (2020)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.G.</ce:initials>
<ce:surname>Liva</ce:surname>
<ce:given-name>S.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Liva, S.G., et al.: Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol. Med. 12(2), e9910 (2020)</ref-fulltext>
<ce:source-text>Liva, S.G., et al.: Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol. Med. 12(2), e9910 (2020)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Complement. Altern. Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>267</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, H., et al.: Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis. BMC Complement. Altern. Med. 19(1), 267 (2019)</ref-fulltext>
<ce:source-text>Liu, H., et al.: Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis. BMC Complement. Altern. Med. 19(1), 267 (2019)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nakamura</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrients</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nakamura, K., et al.: A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 10(2) (2018)</ref-fulltext>
<ce:source-text>Nakamura, K., et al.: A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 10(2) (2018)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>An</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Biochem. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>An, J.M., et al.: Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J. Clin. Biochem. Nutr. 65(2), 109–117 (2019)</ref-fulltext>
<ce:source-text>An, J.M., et al.: Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J. Clin. Biochem. Nutr. 65(2), 109–117 (2019)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Enomoto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Commun</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>323</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1096</first-page>
<last-page>1102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Enomoto, A., et al.: Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun. 323(3), 1096–1102 (2004)</ref-fulltext>
<ce:source-text>Enomoto, A., et al.: Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun. 323(3), 1096–1102 (2004)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.D.</ce:initials>
<ce:surname>Au</ce:surname>
<ce:given-name>E.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>682</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Au, E.D., et al.: The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front. Physiol. 7, 682 (2016)</ref-fulltext>
<ce:source-text>Au, E.D., et al.: The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front. Physiol. 7, 682 (2016)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3059</first-page>
<last-page>3066</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, A., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–3066 (2017)</ref-fulltext>
<ce:source-text>Miller, A., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–3066 (2017)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6(7), e22538 (2011)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6(7), e22538 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Med. (Berl).</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>561</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mantovani, G., et al.: Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl). 78(10), 554–561 (2000)</ref-fulltext>
<ce:source-text>Mantovani, G., et al.: Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl). 78(10), 554–561 (2000)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>White, J.P., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 6(9), e24650 (2011)</ref-fulltext>
<ce:source-text>White, J.P., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 6(9), e24650 (2011)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Differential effects of IL6 and activin A in the development of cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5372</first-page>
<last-page>5382</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res. 76(18), 5372–5382 (2016)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res. 76(18), 5372–5382 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.N.</ce:initials>
<ce:surname>VanderVeen</ce:surname>
<ce:given-name>B.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>385</first-page>
<last-page>397</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>VanderVeen, B.N., et al.: The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6. Exp. Physiol. 104(3), 385–397 (2019)</ref-fulltext>
<ce:source-text>VanderVeen, B.N., et al.: The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6. Exp. Physiol. 104(3), 385–397 (2019)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 is associated with cachexia in patients with prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kuroda</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Urology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>113</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kuroda, K., et al.: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 69(1), 113–117 (2007)</ref-fulltext>
<ce:source-text>Kuroda, K., et al.: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 69(1), 113–117 (2007)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sato</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Clin. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1463</first-page>
<last-page>1470</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sato, H., et al.: Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. Eur. J. Clin. Pharmacol. 72(12), 1463–1470 (2016)</ref-fulltext>
<ce:source-text>Sato, H., et al.: Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. Eur. J. Clin. Pharmacol. 72(12), 1463–1470 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english> IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.G.</ce:initials>
<ce:surname>Eskiler</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bratisl. Lek. Listy</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>819</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eskiler, G.G., et al.: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl. Lek. Listy. 66(11), 819–826 (2019) </ref-fulltext>
<ce:source-text>Eskiler, G.G., et al.: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl. Lek. Listy. 66(11), 819–826 (2019) </ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Steep elevation of blood interleukin6 (IL-6) associated only with late stages of cachexia in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Iwase</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>312</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iwase, S., et al.: Steep elevation of blood interleukin6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur. Cytokine Netw. 15(4), 312–316 (2004)</ref-fulltext>
<ce:source-text>Iwase, S., et al.: Steep elevation of blood interleukin6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur. Cytokine Netw. 15(4), 312–316 (2004)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lipids Health Dis</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Han, J., et al.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ref-fulltext>
<ce:source-text>Han, J., et al.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Talbert</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talbert, E.E., et al.: Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 9(2), 358–368 (2018)</ref-fulltext>
<ce:source-text>Talbert, E.E., et al.: Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 9(2), 358–368 (2018)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2920</first-page>
<last-page>2926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Garcia, J.M., et al.: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab. 90(5), 2920–2926 (2005)</ref-fulltext>
<ce:source-text>Garcia, J.M., et al.: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab. 90(5), 2920–2926 (2005)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Utech</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
<last-page>251</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Utech, A.E., et al.: Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J. Cachexia. Sarcopenia Muscle. 3(4), 245–251 (2012)</ref-fulltext>
<ce:source-text>Utech, A.E., et al.: Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J. Cachexia. Sarcopenia Muscle. 3(4), 245–251 (2012)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>: Possible role for tocilizumab, an antiinterleukin-6 receptor antibody, in treating cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ando</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ando, K., et al.: Possible role for tocilizumab, an antiinterleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31(6), e69–e72 (2013)</ref-fulltext>
<ce:source-text>Ando, K., et al.: Possible role for tocilizumab, an antiinterleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31(6), e69–e72 (2013)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3995</first-page>
<last-page>4002</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 6(13), 3995–4002 (1987)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 6(13), 3995–4002 (1987)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english> Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.G.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>A.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988"/>
<volisspag>
<volume-issue-number>
<vol-first>336</vol-first>
<iss-first>6200</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>688</first-page>
<last-page>690</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Smith, A.G., et al.: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336(6200), 688–690 (1988)</ref-fulltext>
<ce:source-text>Smith, A.G., et al.: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336(6200), 688–690 (1988)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Baumann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<volisspag>
<volume-issue-number>
<vol-first>262</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9756</first-page>
<last-page>9768</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, H., et al.: Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 262(20), 9756–9768 (1987)</ref-fulltext>
<ce:source-text>Baumann, H., et al.: Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 262(20), 9756–9768 (1987)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.H.</ce:initials>
<ce:surname>Patterson</ce:surname>
<ce:given-name>P.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>II. Developmental aspects. Dev Biol</ref-sourcetitle>
<ref-publicationyear first="1977"/>
<volisspag>
<volume-issue-number>
<vol-first>60</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>473</first-page>
<last-page>481</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Patterson, P.H., Chun, L.L.: The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects. Dev Biol. 60(2), 473–481 (1977)</ref-fulltext>
<ce:source-text>Patterson, P.H., Chun, L.L.: The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects. Dev Biol. 60(2), 473–481 (1977)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mori</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Yamaguchi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Abe</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>160</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1085</first-page>
<last-page>1092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mori, M., Yamaguchi, K., Abe, K.: Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 160(3), 1085–1092 (1989)</ref-fulltext>
<ce:source-text>Mori, M., Yamaguchi, K., Abe, K.: Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 160(3), 1085–1092 (1989)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english> Leukemia inhibitory factor (LIF)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Babon</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>533</first-page>
<last-page>544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nicola, N.A., Babon, J.J.: Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26(5), 533–544 (2015)</ref-fulltext>
<ce:source-text>Nicola, N.A., Babon, J.J.: Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26(5), 533–544 (2015)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Robinson</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1994"/>
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1101</first-page>
<last-page>1116</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robinson, R.C., et al.: The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell. 77(7), 1101–1116 (1994)</ref-fulltext>
<ce:source-text>Robinson, R.C., et al.: The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell. 77(7), 1101–1116 (1994)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Hilton</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>267</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10238</first-page>
<last-page>10247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hilton, D.J., Nicola, N.A.: Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 267(15), 10238–10247 (1992)</ref-fulltext>
<ce:source-text>Hilton, D.J., Nicola, N.A.: Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 267(15), 10238–10247 (1992)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988"/>
<volisspag>
<volume-issue-number>
<vol-first>336</vol-first>
<iss-first>6200</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>684</first-page>
<last-page>687</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Williams, R.L., et al.: Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 336(6200), 684–687 (1988)</ref-fulltext>
<ce:source-text>Williams, R.L., et al.: Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 336(6200), 684–687 (1988)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Hilton</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Metcalf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>207</first-page>
<last-page>215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hilton, D.J., Nicola, N.A., Metcalf, D.: Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell. Physiol. 146(2), 207–215 (1991)</ref-fulltext>
<ce:source-text>Hilton, D.J., Nicola, N.A., Metcalf, D.: Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell. Physiol. 146(2), 207–215 (1991)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Ni</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Reprod. Dev</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>63</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>143</first-page>
<last-page>150</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ni, H., et al.: Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. Mol. Reprod. Dev. 63(2), 143–150 (2002)</ref-fulltext>
<ce:source-text>Ni, H., et al.: Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. Mol. Reprod. Dev. 63(2), 143–150 (2002)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.</ce:initials>
<ce:surname>Walker</ce:surname>
<ce:given-name>E.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>592</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Walker, E.C., et al.: Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120(2), 582–592 (2010) </ref-fulltext>
<ce:source-text>Walker, E.C., et al.: Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120(2), 582–592 (2010) </ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Chesnokova</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.J.</ce:initials>
<ce:surname>Auernhammer</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Melmed</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chesnokova, V., Auernhammer, C.J., Melmed, S.: Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 139(5), 2209–2216 (1998)</ref-fulltext>
<ce:source-text>Chesnokova, V., Auernhammer, C.J., Melmed, S.: Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 139(5), 2209–2216 (1998)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Jo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochim. Biophys. Acta</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>1743</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>187</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jo, C., et al.: Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim. Biophys. Acta. 1743(3), 187–197 (2005)</ref-fulltext>
<ce:source-text>Jo, C., et al.: Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim. Biophys. Acta. 1743(3), 187–197 (2005)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>788</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, X., et al.: LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 5(3), 788–801 (2014)</ref-fulltext>
<ce:source-text>Li, X., et al.: LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 5(3), 788–801 (2014)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yue</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3777</first-page>
<last-page>3790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yue, X., et al.: Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget. 7(4), 3777–3790 (2016)</ref-fulltext>
<ce:source-text>Yue, X., et al.: Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget. 7(4), 3777–3790 (2016)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Metcalf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Proc. Natl. Acad. Sci</ref-sourcetitle>
<ref-text>USA</ref-text>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5948</first-page>
<last-page>5952</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Metcalf, D., Gearing, D.P.: Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA. 86(15), 5948–5952 (1989)</ref-fulltext>
<ce:source-text>Metcalf, D., Gearing, D.P.: Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA. 86(15), 5948–5952 (1989)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mori</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6656</first-page>
<last-page>6659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mori, M., et al.: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res. 51(24), 6656–6659 (1991)</ref-fulltext>
<ce:source-text>Mori, M., et al.: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res. 51(24), 6656–6659 (1991)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Kamohara</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Onco</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>977</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamohara, H., et al.: Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int. J. Oncol. 30(4), 977–983 (2007)</ref-fulltext>
<ce:source-text>Kamohara, H., et al.: Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int. J. Oncol. 30(4), 977–983 (2007)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.W.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>387</first-page>
<last-page>494</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chang, J.W., et al.: Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J. Endocrinol. 179(3), 387–394 (2003)</ref-fulltext>
<ce:source-text>Chang, J.W., et al.: Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J. Endocrinol. 179(3), 387–394 (2003)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of cancer cachexiarelated factors in human cancer xenografts: an immunohistochemical analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamoshida</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>281</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamoshida, S., et al.: Expression of cancer cachexiarelated factors in human cancer xenografts: an immunohistochemical analysis. Biomed. Res. 27(6), 275–281 (2006)</ref-fulltext>
<ce:source-text>Kamoshida, S., et al.: Expression of cancer cachexiarelated factors in human cancer xenografts: an immunohistochemical analysis. Biomed. Res. 27(6), 275–281 (2006)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Iseki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jpn. J. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>562</first-page>
<last-page>567</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iseki, H., et al.: Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn. J. Cancer Res. 86(6), 562–567 (1995)</ref-fulltext>
<ce:source-text>Iseki, H., et al.: Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn. J. Cancer Res. 86(6), 562–567 (1995)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jpn. J. Clin</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
<last-page>94</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tanaka, R., et al.: Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn. J. Clin. Oncol. 26(2), 88–94 (1996)</ref-fulltext>
<ce:source-text>Tanaka, R., et al.: Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn. J. Clin. Oncol. 26(2), 88–94 (1996)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Terawaki</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>34748</first-page>
<last-page>34764</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Terawaki, K., et al.: Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats. Oncotarget. 9(78), 34748–34764 (2018)</ref-fulltext>
<ce:source-text>Terawaki, K., et al.: Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats. Oncotarget. 9(78), 34748–34764 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english> A key role for leukemia inhibitory factor in c26 cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.N.</ce:initials>
<ce:surname>Seto</ce:surname>
<ce:given-name>D.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.W.</ce:initials>
<ce:surname>Jackman</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
<iss-first>32</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19976</first-page>
<last-page>19986</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Seto, D.N., Kandarian, S.C., Jackman, R.W.: A key role for leukemia inhibitory factor in c26 cancer cachexia. J. Biol. Chem. 290(32), 19976–19986 (2015)</ref-fulltext>
<ce:source-text>. Seto, D.N., Kandarian, S.C., Jackman, R.W.: A key role for leukemia inhibitory factor in c26 cancer cachexia. J. Biol. Chem. 290(32), 19976–19986 (2015)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.K.</ce:initials>
<ce:surname>Arora</ce:surname>
<ce:given-name>G.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jci Insight</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>14</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arora, G.K., et al.: Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. Jci Insight. 3(14), 26 (2018)</ref-fulltext>
<ce:source-text>Arora, G.K., et al.: Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. Jci Insight. 3(14), 26 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo effect of recombinant human leukemia inhibitory factor in primates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Akiyama</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jpn. J. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>88</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>583</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akiyama, Y., et al.: In vivo effect of recombinant human leukemia inhibitory factor in primates. Jpn. J. Cancer Res. 88(6), 578–583 (1997)</ref-fulltext>
<ce:source-text>Akiyama, Y., et al.: In vivo effect of recombinant human leukemia inhibitory factor in primates. Jpn. J. Cancer Res. 88(6), 578–583 (1997)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1109</first-page>
<last-page>1120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kandarian, S.C., et al.: Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia. Sarcopenia Muscle. 9(6), 1109–1120 (2018)</ref-fulltext>
<ce:source-text>Kandarian, S.C., et al.: Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia. Sarcopenia Muscle. 9(6), 1109–1120 (2018)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Terawaki</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Terawaki, K., et al.: New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am. J. Physiol. Endocrinol. Metab. 306(4), E373–E387 (2014)</ref-fulltext>
<ce:source-text>Terawaki, K., et al.: New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am. J. Physiol. Endocrinol. Metab. 306(4), E373–E387 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.G.</ce:initials>
<ce:surname>Billingsley</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29</first-page>
<last-page>35</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Billingsley, K.G., et al.: Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3(1), 29–35 (1996)</ref-fulltext>
<ce:source-text>Billingsley, K.G., et al.: Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3(1), 29–35 (1996)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Kajimura</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Kajimura, N., et al.: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother. Pharmacol. 38(Suppl), S48–S52 (1996)</ref-fulltext>
<ce:source-text>Kajimura, N., et al.: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother. Pharmacol. 38(Suppl), S48–S52 (1996)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-nataskeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Grounds</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Tissue Res</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>129</first-page>
<last-page>141</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, J.D., Davies, M., Grounds, M.D.: Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-natalskeletal muscle. Cell Tissue Res. 306(1), 129–141 (2001)</ref-fulltext>
<ce:source-text>White, J.D., Davies, M., Grounds, M.D.: Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-natalskeletal muscle. Cell Tissue Res. 306(1), 129–141 (2001)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(/) mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Spangenburg</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.W.</ce:initials>
<ce:surname>Booth</ce:surname>
<ce:given-name>F.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>3</iss-first>
<iss-last>4</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>125</first-page>
<last-page>130</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Spangenburg, E.E., Booth, F.W.: Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(/) mouse. Cytokine. 34(3–4), 125–130 (2006)</ref-fulltext>
<ce:source-text>Spangenburg, E.E., Booth, F.W.: Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(/) mouse. Cytokine. 34(3–4), 125–130 (2006)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic approaches for muscle wasting disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.S.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.D.</ce:initials>
<ce:surname>Schertzer</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.G.</ce:initials>
<ce:surname>Ryall</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol. Ther</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>113</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>461</first-page>
<last-page>487</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lynch, G.S., Schertzer, J.D., Ryall, J.G.: Therapeutic approaches for muscle wasting disorders. Pharmacol. Ther. 113(3), 461–487 (2007)</ref-fulltext>
<ce:source-text>Lynch, G.S., Schertzer, J.D., Ryall, J.G.: Therapeutic approaches for muscle wasting disorders. Pharmacol. Ther. 113(3), 461–487 (2007)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>310</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Gao, S., Carson, J.A.: Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes. Am. J. Physiol. Cell Physiol. 310(1), C66–C79 (2016)</ref-fulltext>
<ce:source-text>Gao, S., Carson, J.A.: Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes. Am. J. Physiol. Cell Physiol. 310(1), C66–C79 (2016)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.K.</ce:initials>
<ce:surname>Marshall</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1994"/>
<volisspag>
<volume-issue-number>
<vol-first>135</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>141</first-page>
<last-page>147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marshall, M.K., et al.: Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology. 135(1), 141–147 (1994)</ref-fulltext>
<ce:source-text>Marshall, M.K., et al.: Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology. 135(1), 141–147 (1994)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FEBS Lett</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>579</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4317</first-page>
<last-page>4323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W., et al.: The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling. FEBS Lett. 579(20), 4317–4323 (2005)</ref-fulltext>
<ce:source-text>He, W., et al.: The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling. FEBS Lett. 579(20), 4317–4323 (2005)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sendtner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurobiol</ref-sourcetitle>
<ref-publicationyear first="1994"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1436</first-page>
<last-page>1453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sendtner, M., et al.: Ciliary neurotrophic factor. J. Neurobiol. 25(11), 1436–1453 (1994)</ref-fulltext>
<ce:source-text>Sendtner, M., et al.: Ciliary neurotrophic factor. J. Neurobiol. 25(11), 1436–1453 (1994)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Sequence and structural organization of the human gene encoding ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lam</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gene</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>271</first-page>
<last-page>276</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lam, A., et al.: Sequence and structural organization of the human gene encoding ciliary neurotrophic factor. Gene. 102(2), 271–276 (1991) </ref-fulltext>
<ce:source-text>Lam, A., et al.: Sequence and structural organization of the human gene encoding ciliary neurotrophic factor. Gene. 102(2), 271–276 (1991) </ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Purification of the chick eye ciliary neuronotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Barbin</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Manthorpe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Varon</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurochem</ref-sourcetitle>
<ref-publicationyear first="1984"/>
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1468</first-page>
<last-page>1478</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barbin, G., Manthorpe, M., Varon, S.: Purification of the chick eye ciliary neuronotrophic factor. J. Neurochem. 43(5), 1468–1478 (1984)</ref-fulltext>
<ce:source-text>Barbin, G., Manthorpe, M., Varon, S.: Purification of the chick eye ciliary neuronotrophic factor. J. Neurochem. 43(5), 1468–1478 (1984)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Hughes</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988"/>
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>6185</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>70</first-page>
<last-page>73</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hughes, S.M., et al.: Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature. 335(6185), 70–73 (1988))</ref-fulltext>
<ce:source-text>Hughes, S.M., et al.: Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature. 335(6185), 70–73 (1988)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The receptor for ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>253</vol-first>
<iss-first>5015</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>63</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Davis, S., et al.: The receptor for ciliary neurotrophic factor. Science. 253(5015), 59–63 (1991)</ref-fulltext>
<ce:source-text>Davis, S., et al.: The receptor for ciliary neurotrophic factor. Science. 253(5015), 59–63 (1991)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.Y.</ce:initials>
<ce:surname>Ip</ce:surname>
<ce:given-name>N.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>89</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ip, N.Y., et al.: The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development. Neuron. 10(1), 89–102 (1993) </ref-fulltext>
<ce:source-text>Ip, N.Y., et al.: The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development. Neuron. 10(1), 89–102 (1993) </ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Regional distribution, developmental changes, and cellular localization of CNTFmRNA and protein in the rat brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Stockli</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>447</first-page>
<last-page>459</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Stockli, K.A., et al.: Regional distribution, developmental changes, and cellular localization of CNTFmRNA and protein in the rat brain. J. Cell Biol. 115(2), 447–459 (1991)</ref-fulltext>
<ce:source-text>. Stockli, K.A., et al.: Regional distribution, developmental changes, and cellular localization of CNTFmRNA and protein in the rat brain. J. Cell Biol. 115(2), 447–459 (1991)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rende</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Glia</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rende, M., et al.: Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve. Glia. 5(1), 25–32 (1992)</ref-fulltext>
<ce:source-text>Rende, M., et al.: Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve. Glia. 5(1), 25–32 (1992)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Friedman</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>295</first-page>
<last-page>305</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedman, B., et al.: Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron. 9(2), 295–305 (1992)</ref-fulltext>
<ce:source-text>Friedman, B., et al.: Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron. 9(2), 295–305 (1992)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sendtner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Stockli</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Thoenen</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sendtner, M., Stockli, K.A., Thoenen, H.: Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 118(1), 139–148 (1992)</ref-fulltext>
<ce:source-text>Sendtner, M., Stockli, K.A., Thoenen, H.: Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 118(1), 139–148 (1992)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines of the LIF/CNTF family and metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Pasquin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.F.</ce:initials>
<ce:surname>Gauchat</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>82</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>122</first-page>
<last-page>124</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pasquin, S., Sharma, M., Gauchat, J.F.: Cytokines of the LIF/CNTF family and metabolism. Cytokine. 82, 122–124 (2016)</ref-fulltext>
<ce:source-text>Pasquin, S., Sharma, M., Gauchat, J.F.: Cytokines of the LIF/CNTF family and metabolism. Cytokine. 82, 122–124 (2016)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english> Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>5</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Martin, D., et al.: Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle. Am. J. Phys. 271(5 Pt 2), R1422–R1428 (1996) </ref-fulltext>
<ce:source-text>Martin, D., et al.: Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle. Am. J. Phys. 271(5 Pt 2), R1422–R1428 (1996) </ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Physiological effects of CNTF-induced wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>J.T.</ce:initials>
</author>
<author seq="2">
<ce:initials>B.J.</ce:initials>
<ce:surname>Mullen</ce:surname>
<ce:given-name>B.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Roder</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>784</first-page>
<last-page>793</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Henderson, J.T., Mullen, B.J., Roder, J.C.: Physiological effects of CNTF-induced wasting. Cytokine. 8(10), 784–793 (1996)</ref-fulltext>
<ce:source-text>Henderson, J.T., Mullen, B.J., Roder, J.C.: Physiological effects of CNTF-induced wasting. Cytokine. 8(10), 784–793 (1996)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic administration of ciliary neurotrophic factor induces cachexia in rodents</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1994"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2632</first-page>
<last-page>2638</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Henderson, J.T., et al.: Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J. Clin. Investig. 93(6), 2632–2638 (1994)</ref-fulltext>
<ce:source-text>Henderson, J.T., et al.: Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J. Clin. Investig. 93(6), 2632–2638 (1994)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.J.</ce:initials>
<ce:surname>Espat</ce:surname>
<ce:given-name>N.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>1</iss-first>
<part>Part 2</part>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Espat, N.J., et al.: Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am. J. Phys. 271(1 Pt 2), R185–R190 (1996)</ref-fulltext>
<ce:source-text>Espat, N.J., et al.: Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am. J. Phys. 271(1 Pt 2), R185–R190 (1996)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Matthys</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Billiau</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>770</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matthys, P., Billiau, A.: Cytokines and cachexia. Nutrition. 13(9), 763–770 (1997)</ref-fulltext>
<ce:source-text>Matthys, P., Billiau, A.: Cytokines and cachexia. Nutrition. 13(9), 763–770 (1997)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Pennica</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1142</first-page>
<last-page>1146</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pennica, D., et al.: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. USA. 92(4), 1142–1146 (1995)</ref-fulltext>
<ce:source-text>Pennica, D., et al.: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. USA. 92(4), 1142–1146 (1995)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stephanou</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell. Cardiol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>849</first-page>
<last-page>855</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephanou, A., et al.: Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J. Mol. Cell. Cardiol. 30(4), 849–855 (1998)</ref-fulltext>
<ce:source-text>Stephanou, A., et al.: Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J. Mol. Cell. Cardiol. 30(4), 849–855 (1998)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kuwahara</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1385</first-page>
<last-page>1394</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kuwahara, K., et al.: Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J. Mol. Cell. Cardiol. 32(8), 1385–1394 (2000)</ref-fulltext>
<ce:source-text>Kuwahara, K., et al.: Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J. Mol. Cell. Cardiol. 32(8), 1385–1394 (2000)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Liver damage using suicide genes. A model for oval cell activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bustos</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>157</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>549</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bustos, M., et al.: Liver damage using suicide genes. A model for oval cell activation. Am. J. Pathol. 157(2), 549–559 (2000)</ref-fulltext>
<ce:source-text>Bustos, M., et al.: Liver damage using suicide genes. A model for oval cell activation. Am. J. Pathol. 157(2), 549–559 (2000)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: Dual roles in antiapoptosis and cell repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Ho</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Arch. Surg</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1077</first-page>
<last-page>1084</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ho, D.W., et al.: Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. Arch. Surg. 141(11), 1077–1084 (2006) discussion 1084</ref-fulltext>
<ce:source-text>Ho, D.W., et al.: Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. Arch. Surg. 141(11), 1077–1084 (2006) discussion 1084</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>3</iss-first>
<iss-last>4</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>101</first-page>
<last-page>106</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine. 36(3–4), 101–106 (2006)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine. 36(3–4), 101–106 (2006)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>The resolution of inflammation: Anti-inflammatory roles for NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Lawrence</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>523</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lawrence, T., Fong, C.: The resolution of inflammation: Anti-inflammatory roles for NF-kappaB. Int. J. Biochem. Cell Biol. 42(4), 519–523 (2010)</ref-fulltext>
<ce:source-text>Lawrence, T., Fong, C.: The resolution of inflammation: Anti-inflammatory roles for NF-kappaB. Int. J. Biochem. Cell Biol. 42(4), 519–523 (2010)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mediat. Inflamm</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>2009</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489802</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. Mediat. Inflamm. 2009, 489802 (2009)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. Mediat. Inflamm. 2009, 489802 (2009)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ichiki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ichiki, T., et al.: Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 294(2), H750–H763 (2008)</ref-fulltext>
<ce:source-text>Ichiki, T., et al.: Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 294(2), H750–H763 (2008)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Chin. Med</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2592</first-page>
<last-page>2598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells. Chin. Med. J. 121(24), 2592–2598 (2008)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells. Chin. Med. J. 121(24), 2592–2598 (2008)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Versatile functions for IL-6 in metabolism and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Mauer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Denson</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Bruning</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Immunol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>92</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mauer, J., Denson, J.L., Bruning, J.C.: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 36(2), 92–101 (2015)</ref-fulltext>
<ce:source-text>Mauer, J., Denson, J.L., Bruning, J.C.: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 36(2), 92–101 (2015)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Andres</ce:surname>
<ce:given-name>Lopez</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hypertension</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>120</first-page>
<last-page>129</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lopez-Andres, N., et al.: Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 61(1), 120–129 (2013)</ref-fulltext>
<ce:source-text>Lopez-Andres, N., et al.: Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 61(1), 120–129 (2013)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 is a key regulator of glucose and lipid metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.M</ce:initials>
<ce:surname>Aliaga</ce:surname>
<ce:given-name>Moreno</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreno-Aliaga, M.J., et al.: Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 14(2), 242–253 (2011)</ref-fulltext>
<ce:source-text>Moreno-Aliaga, M.J., et al.: Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 14(2), 242–253 (2011)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english> Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Limongelli</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>50</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
<last-page>247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Limongelli, G., et al.: Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. 50(3), 245–247 (2010)</ref-fulltext>
<ce:source-text>Limongelli, G., et al.: Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. 50(3), 245–247 (2010)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.F.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Z.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Liver Int</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>622</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yang, Z.F., et al.: Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28(5), 622–631 (2008) </ref-fulltext>
<ce:source-text>Yang, Z.F., et al.: Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28(5), 622–631 (2008) </ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Castano</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hepatol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>60</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1071</first-page>
<last-page>1025</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Castano, D., et al.: Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60(5), 1017–1025 (2014)</ref-fulltext>
<ce:source-text>Castano, D., et al.: Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60(5), 1017–1025 (2014)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Malavazos</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hypertension</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Malavazos, A.E., et al.: Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity. Hypertension. 51(2), e8–e9 (2008) author reply e10</ref-fulltext>
<ce:source-text>Malavazos, A.E., et al.: Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity. Hypertension. 51(2), e8–e9 (2008) author reply e10</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.R.</ce:initials>
<ce:surname>Urteaga</ce:surname>
<ce:given-name>Rendo</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1429</first-page>
<last-page>1436</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rendo-Urteaga, T., et al.: Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism. 62(10), 1429–1436 (2013)</ref-fulltext>
<ce:source-text>Rendo-Urteaga, T., et al.: Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism. 62(10), 1429–1436 (2013)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english> Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.B.</ce:initials>
<ce:surname>Heider</ce:surname>
<ce:given-name>Barnabe</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barnabe-Heider, F., et al.: Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron. 48(2), 253–265 (2005) </ref-fulltext>
<ce:source-text>Barnabe-Heider, F., et al.: Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron. 48(2), 253–265 (2005) </ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.H.</ce:initials>
<ce:surname>Freed</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiovasc. Res</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>782</first-page>
<last-page>792</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freed, D.H., et al.: Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc. Res. 65(4), 782–792 (2005)</ref-fulltext>
<ce:source-text>Freed, D.H., et al.: Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc. Res. 65(4), 782–792 (2005)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english> A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ishikawa</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hypertens</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>807</first-page>
<last-page>816</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ishikawa, M., et al.: A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J. Hypertens. 17(6), 807–816 (1999)</ref-fulltext>
<ce:source-text>Ishikawa, M., et al.: A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J. Hypertens. 17(6), 807–816 (1999)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Heart Vessel</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>199</first-page>
<last-page>208</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, J., et al.: Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessel. 13(4), 199–208 (1998)</ref-fulltext>
<ce:source-text>Pan, J., et al.: Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessel. 13(4), 199–208 (1998)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>Tuberculous aneurysms of the aorta</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Talwar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.K.</ce:initials>
<ce:surname>Choudhary</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Cardiovasc. Surg</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1184</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talwar, S., Choudhary, S.K.: Tuberculous aneurysms of the aorta. J. Thorac. Cardiovasc. Surg. 125(5), 1184 (2003)</ref-fulltext>
<ce:source-text>Talwar, S., Choudhary, S.K.: Tuberculous aneurysms of the aorta. J. Thorac. Cardiovasc. Surg. 125(5), 1184 (2003)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Is plasma cardiotrophin-1 a marker of hypertensive heart disease?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Lopez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hypertens</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>625</first-page>
<last-page>632</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lopez, B., et al.: Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J. Hypertens. 23(3), 625–632 (2005)</ref-fulltext>
<ce:source-text>Lopez, B., et al.: Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J. Hypertens. 23(3), 625–632 (2005)</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>The enigmatic cytokine oncostatin m and roles in disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.D.</ce:initials>
<ce:surname>Richards</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ISRN Inflamm</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Richards, C.D.: The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013)</ref-fulltext>
<ce:source-text>Richards, C.D.: The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Argast</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cells Tissues Organs</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>193</vol-first>
<iss-first>1</iss-first>
<iss-last>2</vol-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>114</first-page>
<last-page>132</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argast, G.M., et al.: Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193(1–2), 114–132 (2011)</ref-fulltext>
<ce:source-text>Argast, G.M., et al.: Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193(1–2), 114–132 (2011)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Deng</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1519</first-page>
<last-page>1526</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deng, G., et al.: Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin. Cancer Res. 15(5), 1519–1526 (2009)</ref-fulltext> 
<ce:source-text>Deng, G., et al.: Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin. Cancer Res. 15(5), 1519–1526 (2009) </ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english> A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Chollangi</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32848</first-page>
<last-page>32859</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chollangi, S., et al.: A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J. Biol. Chem. 287(39), 32848–32859 (2012)</ref-fulltext>
<ce:source-text>Chollangi, S., et al.: A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J. Biol. Chem. 287(39), 32848–32859 (2012)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Junk</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4001</first-page>
<last-page>4013</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Junk, D.J., et al.: Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene. 36(28), 4001–4013 (2017)</ref-fulltext>
<ce:source-text>Junk, D.J., et al.: Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene. 36(28), 4001–4013 (2017)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english> Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Pradeep</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomarkers</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>277</first-page>
<last-page>282</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pradeep, A.R., et al.: Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers. 15(3), 277–282 (2010)</ref-fulltext>
<ce:source-text>Pradeep, A.R., et al.: Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers. 15(3), 277–282 (2010)</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english> Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hasegawa</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Rheumatol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>308</first-page>
<last-page>313</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hasegawa, M., et al.: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25(2), 308–313 (1998)</ref-fulltext>
<ce:source-text>Hasegawa, M., et al.: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25(2), 308–313 (1998)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Biomark</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>171</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, H., et al.: Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 11(4), 161–171 (2012)</ref-fulltext>
<ce:source-text>Liang, H., et al.: Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 11(4), 161–171 (2012)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Robak</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robak, E., et al.: Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 8(3), 281–286 (1997)</ref-fulltext>
<ce:source-text>Robak, E., et al.: Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 8(3), 281–286 (1997)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M: potential implications for malignancy and metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Elks</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Des</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>25</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3645</first-page>
<last-page>3657</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, J.M., Elks, C.M.: Oncostatin M: potential implications for malignancy and metabolism. Curr. Pharm. Des. 23(25), 3645–3657 (2017)</ref-fulltext>
<ce:source-text>Stephens, J.M., Elks, C.M.: Oncostatin M: potential implications for malignancy and metabolism. Curr. Pharm. Des. 23(25), 3645–3657 (2017)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Miki</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>516</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>951</first-page>
<last-page>956</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miki, Y., et al.: Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem. Biophys. Res. Commun. 516(3), 951–956 (2019)</ref-fulltext>
<ce:source-text>Miki, Y., et al.: Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem. Biophys. Res. Commun. 516(3), 951–956 (2019)</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.E.</ce:initials>
<ce:surname>Sands</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Aliment. Pharmacol. Ther</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>406</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sands, B.E., et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment. Pharmacol. Ther. 16(3), 399–406 (2002)</ref-fulltext>
<ce:source-text>Sands, B.E., et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment. Pharmacol. Ther. 16(3), 399–406 (2002)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11: a multifunctional cytokine with intrinsically disordered regions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>Permyakov</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.N.</ce:initials>
<ce:surname>Uversky</ce:surname>
<ce:given-name>V.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.E.</ce:initials>
<ce:surname>Permyakov</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biochem</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>296</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Permyakov, E.A., Uversky, V.N., Permyakov, S.E.: Interleukin-11: a multifunctional cytokine with intrinsically disordered regions. Cell Biochem. Biophys. 74(3), 285–296 (2016)</ref-fulltext>
<ce:source-text>Permyakov, E.A., Uversky, V.N., Permyakov, S.E.: Interleukin-11: a multifunctional cytokine with intrinsically disordered regions. Cell Biochem. Biophys. 74(3), 285–296 (2016)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english> The dynamics of signal triggering in a gp130-receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Matadeen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Structure</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>448</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matadeen, R., et al.: The dynamics of signal triggering in a gp130-receptor complex. Structure. 15(4), 441–448 (2007)</ref-fulltext>
<ce:source-text>Matadeen, R., et al.: The dynamics of signal triggering in a gp130-receptor complex. Structure. 15(4), 441–448 (2007)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11 signals through the formation of a hexameric receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.A.</ce:initials>
<ce:surname>Barton</ce:surname>
<ce:given-name>V.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>275</vol-first>
<iss-first>46</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36197</first-page>
<last-page>36203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barton, V.A., et al.: Interleukin-11 signals through the formation of a hexameric receptor complex. J. Biol. Chem. 275(46), 36197–36203 (2000)</ref-fulltext>
<ce:source-text>Barton, V.A., et al.: Interleukin-11 signals through the formation of a hexameric receptor complex. J. Biol. Chem. 275(46), 36197–36203 (2000)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3- activating cytokines: a therapeutic opportunity for inflammatory bowel disease?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.M.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Interf. Cytokine</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>350</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, P.M., Putoczki, T.L., Ernst, M.: STAT3- activating cytokines: a therapeutic opportunity for inflammatory bowel disease? J. Interf. Cytokine Res. 35(5), 340–350 (2015)</ref-fulltext>
<ce:source-text>Nguyen, P.M., Putoczki, T.L., Ernst, M.: STAT3- activating cytokines: a therapeutic opportunity for inflammatory bowel disease? J. Interf. Cytokine Res. 35(5), 340–350 (2015)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Hematopoietic, immunomodulatory and epithelial effects of interleukin-11</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.S.</ce:initials>
<ce:surname>Schwertschlag</ce:surname>
<ce:given-name>U.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Leukemia</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1315</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schwertschlag, U.S., et al.: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 13(9), 1307–1315 (1999)</ref-fulltext>
<ce:source-text>Schwertschlag, U.S., et al.: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 13(9), 1307–1315 (1999)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Leukoc. Biol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>88</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1109</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Putoczki, T., Ernst, M.: More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88(6), 1109–1117 (2010) </ref-fulltext>
<ce:source-text>Putoczki, T., Ernst, M.: More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88(6), 1109–1117 (2010) </ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Wan</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>138</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wan, B., et al.: Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study. Cytokine. 76(2), 138–143 (2015)</ref-fulltext>
<ce:source-text>Wan, B., et al.: Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study. Cytokine. 76(2), 138–143 (2015)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Obana</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Obana, M., et al.: Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am. J. Physiol. Heart Circ. Physiol. 303(5), H569– H577 (2012)</ref-fulltext>
<ce:source-text>Obana, M., et al.: Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am. J. Physiol. Heart Circ. Physiol. 303(5), H569– H577 (2012)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kimura</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>107</first-page>
<last-page>115</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kimura, R., et al.: Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine. 38(2), 107–115 (2007)</ref-fulltext>
<ce:source-text>Kimura, R., et al.: Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine. 38(2), 107–115 (2007)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Obana</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>684</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obana, M., et al.: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 121(5), 684–691 (2010)</ref-fulltext>
<ce:source-text>Obana, M., et al.: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 121(5), 684–691 (2010)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting IL-11 signaling in colon cancer. Oncotarget</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1860</first-page>
<last-page>1861</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ernst, M., Putoczki, T.L.: Targeting IL-11 signaling in colon cancer. Oncotarget. 4(11), 1860–1861 (2013)</ref-fulltext>
<ce:source-text>Ernst, M., Putoczki, T.L.: Targeting IL-11 signaling in colon cancer. Oncotarget. 4(11), 1860–1861 (2013)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.N.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>C.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>498</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, C.N., et al.: Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26(5), 489–498 (2015)</ref-fulltext>
<ce:source-text>Johnstone, C.N., et al.: Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26(5), 489–498 (2015)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Winship</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>720</first-page>
<last-page>730</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Winship, A.L., et al.: Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol. Cancer Ther. 15(4), 720–730 (2016) </ref-fulltext>
<ce:source-text>Winship, A.L., et al.: Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol. Cancer Ther. 15(4), 720–730 (2016) </ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11: a multifunctional cytokine with intrinsically disordered regions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Putoczki, T.L., et al.: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24(2), 257–271 (2013)</ref-fulltext>
<ce:source-text>Putoczki, T.L., et al.: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24(2), 257–271 (2013)</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.N.</ce:initials>
<ce:surname>Ashizawa</ce:surname>
<ce:given-name>Nara</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3381</first-page>
<last-page>3387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nara-Ashizawa, N., et al.: Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res. 21(5), 3381–3387 (2001) </ref-fulltext>
<ce:source-text>Nara-Ashizawa, N., et al.: Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res. 21(5), 3381–3387 (2001) </ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Saitoh</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saitoh, M., et al.: Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother. Pharmacol. 49(2), 161–166 (2002)</ref-fulltext>
<ce:source-text>Saitoh, M., et al.: Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother. Pharmacol. 49(2), 161–166 (2002)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Binding of madindoline A to the extracellular domain of gp130</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.Z.</ce:initials>
<ce:surname>Saleh</ce:surname>
<ce:given-name>A.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochemistry</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>32</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10822</first-page>
<last-page>10827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saleh, A.Z., et al.: Binding of madindoline A to the extracellular domain of gp130. Biochemistry. 44(32), 10822–10827 (2005)</ref-fulltext>
<ce:source-text>Saleh, A.Z., et al.: Binding of madindoline A to the extracellular domain of gp130. Biochemistry. 44(32), 10822–10827 (2005)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Siegmund</ce:surname>
<ce:given-name>Aparicio</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2131</first-page>
<last-page>2148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aparicio-Siegmund, S., et al.: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget. 5(8), 2131–2148 (2014)</ref-fulltext>
<ce:source-text>Aparicio-Siegmund, S., et al.: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget. 5(8), 2131–2148 (2014)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and antiinflammatory proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Diegelmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>286</first-page>
<last-page>298</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Diegelmann, J., et al.: A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and antiinflammatory proteins. J. Biol. Chem. 287(1), 286–298 (2012)</ref-fulltext>
<ce:source-text>Diegelmann, J., et al.: A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and antiinflammatory proteins. J. Biol. Chem. 287(1), 286–298 (2012)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>The biology of interleukin-27 reveals unique pro- and antiinflammatory functions in immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Siegmund</ce:surname>
<ce:given-name>Aparicio</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Garbers</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>579</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aparicio-Siegmund, S., Garbers, C.: The biology of interleukin-27 reveals unique pro- and antiinflammatory functions in immunity. Cytokine Growth Factor Rev. 26(5), 579–586 (2015)</ref-fulltext>
<ce:source-text>Aparicio-Siegmund, S., Garbers, C.: The biology of interleukin-27 reveals unique pro- and antiinflammatory functions in immunity. Cytokine Growth Factor Rev. 26(5), 579–586 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>The immunobiology of IL-27</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.O.</ce:initials>
<ce:surname>Hall</ce:surname>
<ce:given-name>A.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Silver</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Hunter</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Immunol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>155</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hall, A.O., Silver, J.S., Hunter, C.A.: The immunobiology of IL-27. Adv. Immunol. 115, 1–44 (2012)</ref-fulltext>
<ce:source-text>Hall, A.O., Silver, J.S., Hunter, C.A.: The immunobiology of IL-27. Adv. Immunol. 115, 1–44 (2012)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Pflanz</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>779</first-page>
<last-page>790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pflanz, S., et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 16(6), 779–790 (2002)</ref-fulltext>
<ce:source-text>Pflanz, S., et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 16(6), 779–790 (2002)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical implications of the interleukin 27 serum level in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Investig. Med</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>627</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, D., et al.: Clinical implications of the interleukin 27 serum level in breast cancer. J. Investig. Med. 62(3), 627–631 (2014)</ref-fulltext>
<ce:source-text>Lu, D., et al.: Clinical implications of the interleukin 27 serum level in breast cancer. J. Investig. Med. 62(3), 627–631 (2014)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Chiyo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>437</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chiyo, M., et al.: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer. 115(3), 437–442 (2005)</ref-fulltext>
<ce:source-text>Chiyo, M., et al.: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer. 115(3), 437–442 (2005)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Potent antitumor activity of interleukin-27</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hisada</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1152</first-page>
<last-page>1156</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hisada, M., et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64(3), 1152–1156 (2004)</ref-fulltext>
<ce:source-text>Hisada, M., et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64(3), 1152–1156 (2004)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Salcedo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>182</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4328</first-page>
<last-page>4338</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Salcedo, R., et al.: Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182(7), 4328–4338 (2009)</ref-fulltext>
<ce:source-text>Salcedo, R., et al.: Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182(7), 4328–4338 (2009)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Salcedo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7170</first-page>
<last-page>7182</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Salcedo, R., et al.: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173(12), 7170–7182 (2004)</ref-fulltext>
<ce:source-text>Salcedo, R., et al.: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173(12), 7170–7182 (2004)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Scand. J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>276</first-page>
<last-page>282</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Q., et al.: Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand. J. Immunol. 80(4), 276–282 (2014)</ref-fulltext>
<ce:source-text>Li, Q., et al.: Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand. J. Immunol. 80(4), 276–282 (2014)</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Fitzgerald</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1372</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fitzgerald, D.C., et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8(12), 1372–1379 (2007)</ref-fulltext>
<ce:source-text>Fitzgerald, D.C., et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8(12), 1372–1379 (2007)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english> Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Stumhofer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1363</first-page>
<last-page>1371</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stumhofer, J.S., et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8(12), 1363–1371 (2007)</ref-fulltext>
<ce:source-text>Stumhofer, J.S., et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8(12), 1363–1371 (2007)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Pot</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>797</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pot, C., et al.: Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183(2), 797–801 (2009)</ref-fulltext>
<ce:source-text>Pot, C., et al.: Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183(2), 797–801 (2009)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Owaki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7579</first-page>
<last-page>7587</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Owaki, T., et al.: IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177(11), 7579–7587 (2006)</ref-fulltext>
<ce:source-text>Owaki, T., et al.: IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177(11), 7579–7587 (2006)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.G.</ce:initials>
<ce:surname>Findlay</ce:surname>
<ce:given-name>Gwyer</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>190</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4553</first-page>
<last-page>4561</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gwyer Findlay, E., et al.: IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection. J. Immunol. 190(9), 4553–4561 (2013)</ref-fulltext>
<ce:source-text>Gwyer Findlay, E., et al.: IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection. J. Immunol. 190(9), 4553–4561 (2013)</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 induces the production of IgG1 by human B cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boumendjel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boumendjel, A., et al.: IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 17(4), 281–289 (2006)</ref-fulltext>
<ce:source-text>Boumendjel, A., et al.: IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 17(4), 281–289 (2006)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Differential effects of IL-27 on human B cell subsets</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Larousserie</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5890</first-page>
<last-page>5897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Larousserie, F., et al.: Differential effects of IL-27 on human B cell subsets. J. Immunol. 176(10), 5890–5897 (2006)</ref-fulltext>
<ce:source-text>Larousserie, F., et al.: Differential effects of IL-27 on human B cell subsets. J. Immunol. 176(10), 5890–5897 (2006)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>New IL-6 (gp130) family cytokine members, CLC/NNT1/ BSF3 and IL-27</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Murakami</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Kamimura</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Hirano</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Growth Factors</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>75</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murakami, M., Kamimura, D., Hirano, T.: New IL-6 (gp130) family cytokine members, CLC/NNT1/ BSF3 and IL-27. Growth Factors. 22(2), 75–77 (2004)</ref-fulltext>
<ce:source-text>Murakami, M., Kamimura, D., Hirano, T.: New IL-6 (gp130) family cytokine members, CLC/NNT1/ BSF3 and IL-27. Growth Factors. 22(2), 75–77 (2004)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Novel neurotrophin-1/B cellstimulating factor-3: a cytokine of the IL-6 family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Senaldi</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci</ref-sourcetitle>
<ref-text>USA</ref-text>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11458</first-page>
<last-page>11463</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senaldi, G., et al.: Novel neurotrophin-1/B cellstimulating factor-3: a cytokine of the IL-6 family.Proc. Natl. Acad. Sci. USA. 96(20), 11458–11463 (1999)</ref-fulltext>
<ce:source-text>Senaldi, G., et al.: Novel neurotrophin-1/B cellstimulating factor-3: a cytokine of the IL-6 family.Proc. Natl. Acad. Sci. USA. 96(20), 11458–11463 (1999)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english> Computational EST database analysis identifies a novel member of the neuropoietic cytokine family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>262</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>138</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, Y., et al.: Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. Biochem. Biophys. Res. Commun. 262(1), 132–138 (1999)</ref-fulltext>
<ce:source-text>Shi, Y., et al.: Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. Biochem. Biophys. Res. Commun. 262(1), 132–138 (1999)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english> Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Benigni</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>87</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1851</first-page>
<last-page>1854</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benigni, F., et al.: Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood. 87(5), 1851–1854 (1996)</ref-fulltext>
<ce:source-text>Benigni, F., et al.: Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood. 87(5), 1851–1854 (1996)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>Novel neurotrophin-1/B cellstimulating factor-3 (NNT-1/BSF-3)/cardiotrophinlike cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vlotides</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>325</first-page>
<last-page>336</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vlotides, G., et al.: Novel neurotrophin-1/B cellstimulating factor-3 (NNT-1/BSF-3)/cardiotrophinlike cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions. Cytokine Growth Factor Rev. 15(5), 325–336 (2004)</ref-fulltext>
<ce:source-text>Vlotides, G., et al.: Novel neurotrophin-1/B cellstimulating factor-3 (NNT-1/BSF-3)/cardiotrophinlike cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions. Cytokine Growth Factor Rev. 15(5), 325–336 (2004)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.P.</ce:initials>
<ce:surname>Favreau</ce:surname>
<ce:given-name>Plun</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1692</first-page>
<last-page>1703</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Plun-Favreau, H., et al.: The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J. 20(7), 1692–1703 (2001)</ref-fulltext>
<ce:source-text>Plun-Favreau, H., et al.: The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J. 20(7), 1692–1703 (2001)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-like cytokine/ cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.G.</ce:initials>
<ce:surname>Forger</ce:surname>
<ce:given-name>N.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8854</first-page>
<last-page>8858</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Forger, N.G., et al.: Cardiotrophin-like cytokine/ cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J. Neurosci. 23(26), 8854–8858 (2003) </ref-fulltext>
<ce:source-text>Forger, N.G., et al.: Cardiotrophin-like cytokine/ cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J. Neurosci. 23(26), 8854–8858 (2003) </ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Uemura</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>7</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Uemura, A., et al.: Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3. Cytokine. 18(1), 1–7 (2002)</ref-fulltext>
<ce:source-text>Uemura, A., et al.: Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3. Cytokine. 18(1), 1–7 (2002)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Novel regulators of kidney development from the tips of the ureteric bud</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Schmidt-Ott</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Soc. Nephrol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1993</first-page>
<last-page>2002</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt-Ott, K.M., et al.: Novel regulators of kidney development from the tips of the ureteric bud. J. Am. Soc. Nephrol. 16(7), 1993–2002 (2005)</ref-fulltext>
<ce:source-text>Schmidt-Ott, K.M., et al.: Novel regulators of kidney development from the tips of the ureteric bud. J. Am. Soc. Nephrol. 16(7), 1993–2002 (2005)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>Suckling defect in mice lacking the soluble haemopoietin receptor NR6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.S.</ce:initials>
<ce:surname>Alexander</ce:surname>
<ce:given-name>W.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Biol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>605</first-page>
<last-page>608</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Alexander, W.S., et al.: Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr. Biol. 9(11), 605–608 (1999)</ref-fulltext>
<ce:source-text>Alexander, W.S., et al.: Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr. Biol. 9(11), 605–608 (1999)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.C.</ce:initials>
<ce:surname>Elson</ce:surname>
<ce:given-name>G.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1371</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elson, G.C., et al.: Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family. J. Immunol. 161(3), 1371–1379 (1998) </ref-fulltext>
<ce:source-text>Elson, G.C., et al.: Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family. J. Immunol. 161(3), 1371–1379 (1998) </ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Vicent</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5744</first-page>
<last-page>5756</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vicent, S., et al.: Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72(22), 5744–5756 (2012)</ref-fulltext>
<ce:source-text>Vicent, S., et al.: Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72(22), 5744–5756 (2012)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Puppa</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J.</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>998</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puppa, M.J., et al.: Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28(2), 998–1009 (2014)</ref-fulltext>
<ce:source-text>Puppa, M.J., et al.: Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28(2), 998–1009 (2014)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-website>
<ce:e-address type="url">Clinicaltrials.gov</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clinicaltrials.gov</ref-fulltext>
<ce:source-text>Clinicaltrials.gov
</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging treatment options for cancerassociated cachexia: a literature review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ther. Clin. Risk Manag</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1266</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T.: Emerging treatment options for cancerassociated cachexia: a literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ref-fulltext>
<ce:source-text>Naito, T.: Emerging treatment options for cancerassociated cachexia: a literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies against cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur J Transl Myol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7960</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., et al.: Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 29(1), 7960 (2019)</ref-fulltext>
<ce:source-text>Argilés, J.M., et al.: Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 29(1), 7960 (2019)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Belloum</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.R.</ce:initials>
<ce:surname>Bekono</ce:surname>
<ce:given-name>Rannou</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.B.</ce:initials>
<ce:surname>Favier</ce:surname>
<ce:given-name>F.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2543</first-page>
<last-page>2552</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Belloum, Y., Rannou-Bekono, F., Favier, F.B.: Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). Oncol. Rep. 37(5), 2543–2552 (2017)</ref-fulltext>
<ce:source-text>Belloum, Y., Rannou-Bekono, F., Favier, F.B.: Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). Oncol. Rep. 37(5), 2543–2552 (2017)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-cytokines in the treatment of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Qian</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann Palliat Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>67</first-page>
<last-page>79</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Prado, B.L., Qian, Y.: Anti-cytokines in the treatment of cancer cachexia. Ann Palliat Med. 8(1), 67–79 (2019)</ref-fulltext>
<ce:source-text>Prado, B.L., Qian, Y.: Anti-cytokines in the treatment of cancer cachexia. Ann Palliat Med. 8(1), 67–79 (2019)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>Endpoints in clinical trials in cancer cachexia: where to start? Curr</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Laird, B.J.A., Balstad, T.R., Solheim, T.S.: Endpoints in clinical trials in cancer cachexia: where to start? Curr. Opin. Support. Palliat. Care. 12(4), 445–452 (2018)</ref-fulltext>
<ce:source-text>Laird, B.J.A., Balstad, T.R., Solheim, T.S.: Endpoints in clinical trials in cancer cachexia: where to start? Curr. Opin. Support. Palliat. Care. 12(4), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>A critical review of multimodal interventions for cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McKeaveney</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Nutr</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>McKeaveney, C., et al.: A critical review of multimodal interventions for cachexia. Adv. Nutr. (2020)</ref-fulltext>
<ce:source-text>McKeaveney, C., et al.: A critical review of multimodal interventions for cachexia. Adv. Nutr. (2020)</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Management of cancer cachexia: ASCO guideline</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Roeland</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2438</first-page>
<last-page>2453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roeland, E.J., et al.: Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38(21), 2438–2453 (2020)</ref-fulltext>
<ce:source-text>Roeland, E.J., et al.: Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38(21), 2438–2453 (2020)</ce:source-text>
</reference>
<reference seq="232">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: impact, mechanisms and emerging treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.C.</ce:initials>
<ce:surname>Vaughan</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.A.</ce:initials>
<ce:surname>Lewandowski</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>95</first-page>
<last-page>109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vaughan, V.C., Martin, P., Lewandowski, P.A.: Cancer cachexia: impact, mechanisms and emerging treatments. J. Cachexia. Sarcopenia Muscle. 4(2), 95–109 (2013)</ref-fulltext>
<ce:source-text>Vaughan, V.C., Martin, P., Lewandowski, P.A.: Cancer cachexia: impact, mechanisms and emerging treatments. J. Cachexia. Sarcopenia Muscle. 4(2), 95–109 (2013)</ce:source-text>
</reference>
<reference seq="233">
<ref-info>
<ref-title>
<ref-titletext-english>Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Rigas</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Onco</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>15</iss-first>
<Supplement>suppl</Supplement>
</volume-issue-number>
<page-information>
<pages>
<first-page>7622</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rigas, J.R., et al.: Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28(15_suppl), 7622–7622 (2010)</ref-fulltext>
<ce:source-text>Rigas, J.R., et al.: Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28(15_suppl), 7622–7622 (2010)</ce:source-text>
</reference>
<reference seq="234">
<ref-info>
<ref-title>
<ref-titletext-english>Favorable responses to tocilizumab in two patients with cancer-related cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hirata</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hirata, H., et al.: Favorable responses to tocilizumab in two patients with cancer-related cachexia. J. Pain Symptom Manag. 46(2), e9–e13 (2013)</ref-fulltext>
<ce:source-text>Hirata, H., et al.: Favorable responses to tocilizumab in two patients with cancer-related cachexia. J. Pain Symptom Manag. 46(2), e9–e13 (2013)</ce:source-text>
</reference>
<reference seq="235">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of tocilizumab in the treatment of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Berti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>23</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2970</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berti, A., et al.: Assessment of tocilizumab in the treatment of cancer cachexia. J. Clin. Oncol. 31(23), 2970 (2013)</ref-fulltext>
<ce:source-text>Berti, A., et al.: Assessment of tocilizumab in the treatment of cancer cachexia. J. Clin. Oncol. 31(23), 2970 (2013)</ce:source-text>
</reference>
<reference seq="236">
<ref-info>
<ref-title>
<ref-titletext-english>PACTO: a single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>266</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Chen, I., et al.: PACTO: a single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Ann. Oncol. 28, v266 (2017)</ref-fulltext>
<ce:source-text>. Chen, I., et al.: PACTO: a single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Ann. Oncol. 28, v266 (2017)</ce:source-text>
</reference>
<reference seq="237">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.G.</ce:initials>
<ce:surname>Favalli</ce:surname>
<ce:given-name>E.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biochem</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>473</first-page>
<last-page>516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Favalli, E.G.: Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 7(3), 473–516 (2020)</ref-fulltext>
<ce:source-text>Favalli, E.G.: Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 7(3), 473–516 (2020)</ce:source-text>
</reference>
<reference seq="238">
<ref-info>
<ref-title>
<ref-titletext-english>Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.H.</ce:initials>
<ce:surname>Heo</ce:surname>
<ce:given-name>T.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wahler</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Suh</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15460</first-page>
<last-page>15473</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heo, T.H., Wahler, J., Suh, N.: Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 7(13), 15460–15473 (2016)</ref-fulltext>
<ce:source-text>Heo, T.H., Wahler, J., Suh, N.: Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 7(13), 15460–15473 (2016)</ce:source-text>
</reference>
<reference seq="239">
<ref-info>
<ref-title>
<ref-titletext-english>Pantoprazole blocks the JAK2/ STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>39640</first-page>
<last-page>39648</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, D., et al.: Pantoprazole blocks the JAK2/ STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 8(24), 39640–39648 (2017) </ref-fulltext>
<ce:source-text>Guo, D., et al.: Pantoprazole blocks the JAK2/ STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 8(24), 39640–39648 (2017)</ce:source-text>
</reference>
<reference seq="240">
<ref-info>
<ref-title>
<ref-titletext-english>Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Reddel</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Thromb. Haemost</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>477</first-page>
<last-page>486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Reddel, C.J., et al.: Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J. Thromb. Haemost. 15(3), 477–486 (2017)</ref-fulltext>
<ce:source-text>Reddel, C.J., et al.: Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J. Thromb. Haemost. 15(3), 477–486 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>